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ABSTRACT 
The genus Echinacea is composed of nine species distributed across central and 
eastern North America that differ in morphology and phytochemistry. Traditionally, these 
plants were used as anti-inflammatory agents or for wound healing. Today, Echinacea 
phytomedicines are most often consumed to prevent or treat upper respiratory infections 
caused by orthomyxoviruses (such as influenza) and rhinoviruses (such as "colds"). In this 
dissertation, we explored the immunomodulatory properties of seven Echinacea species 
using in vitro human adult peripheral blood mononuclear cell (PBMC) models. All of the 
seven Echinacea spp. tested harbored immunomodulatory properties, but they were 
heterogeneous between species and varied by plant organ. Extract factors (such as 
extraction technique, drying time of plant material before extraction, extract storage 
temperature, and extract storage time) were all important factors that worked together to 
determine the immunomodulatory properties of a particular preparation. Lay herbalist 
techniques yielded extracts with immunomodulatory properties. Factors such as species 
selection, plant organ selection, extraction technique, and extract storage conditions need to 
be reported in scientific articles to allow for a more accurate comparison of findings across 
studies. 
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CHAPTER 1. GENERAL INTRODUCTION 
LITERATURE REVIEW 
Botany 
The monophyletic plant genus Echinacea Moench (Asteraceae [Composite]) consists 
of nine species restricted to the American continent: E. angustifolia DC., E. atrorubens Nutt., 
E. laevigata (C. L. Boynt & Beadle) Blake, E. pallida (Nutt.) Nutt., E. paradoxa (J. B. S. 
Norton) Britt., E. purpurea (L.) Moench, E. sanguinea Nutt., E. simulata R. L. McGregor, 
and E. tennesseensis (Beadle) Small [1,2], While individual species vary in their geographic 
ranges, the genus overall is found in the central and eastern United States and some northern 
regions of Mexico, tending to inhabit prairies and other grassland-type habitats. Species vary 
in their abundance: E. angustifolia is prolific throughout much of the U.S., while both E. 
laevigata and E. tennesseensis are listed as federally endangered. 
All members of the genus are herbaceous perennials with inflorescences typical of the 
family, consisting of both ray and disk flowers [3], The ray flowers (which can be white, 
yellow, pink, or purple) encircle the typically conical arrangement of disk flowers, leading to 
the vernacular name for the genus, the coneflowers (echinos, Greek, "spiny, prickly; 
hedgehog"). Leaves arise from the base, typically in a rosette organization, where they 
subtend one to several annual stems. Most members are taprooted, with the exception of 
Echinacea purpurea (fibrous rooted). 
Based on a novel morphometric analysis, one team has recently proposed a revision 
of McGregor's taxonomy [4]; however, their revision has been repeatedly discounted by a 
number of reviewers and genetic data [5,6]. Most members are diploid, with the exception 
of E. pallida (a tetraploid) and some autotetraploid E. angustifolia subspecies. Of the three 
commercially important species examined, gene flow appears to be continuous for E. pallida 
and E. purpurea, but may be discontinuous for E. angustifolia, and there is considerable 
genetic diversity between accessions of E. angustifolia and E. pallida [5]; further, these three 
species exhibit high degrees of genetic difference between each other [7], 
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Ethnobotany 
Native Americans have a long history of using Echinacea spp. for medicinal 
purposes. It was principally used as an anti-inflammatory agent [8], and tangentially to 
relieve pain or treat wounds (such as burns or snakebites). Rarely it was used as a painkiller 
for conditions such as toothaches [9], For these purposes, the root is used most frequently, 
though occasionally leaves and flowering tops are also employed [10]. 
The first mention of Echinacea in Western medical literature occurred in 1762 where 
it was indicated for horse saddle sores, and was briefly investigated scientifically before 
falling into temporary obscurity [11]. It reemerged in the late nineteenth century when Dr. 
Meyer first marketed it as a "blood purifier," where after Lloyd Bros, produced the first 
commercial preparation based on his formulation [10]. Due to the political and social 
climate of the USA in 1910s, Echinacea use was again abandoned, but in Europe it was 
burgeoning [11]. It prospered in Europe both commercially and scientifically throughout the 
20th century, returning to the USA and slowly regaining stature during the 1970s. Today, 
Echinacea spp. are most widely used to prevent and treat upper respiratory infections such as 
rhinoviruses (colds) and influenza [12-14], Commercial preparations typically consist of one 
or a combination of three species: E. angustifolia, E. pallida, and E. purpurea. It is worth 
pointing out that Native Americans never used Echinacea in this context; the use of 
Echinacea for these infections is a recent European invention. 
Effectiveness 
Several clinical and laboratory investigations have attempted to validate or refute the 
efficacy of Echinacea spp. phytomedicines in the context of its current and historical 
medicinal uses. In this section, we will review its effectiveness in treating infections, as an 
anti-inflammatory agent, and in other miscellaneous medical contexts. A subsequent section 
will address specific immunomodulatory capabilities. 
Most clinical research has focused on the effectiveness of Echinacea preparations in 
treating upper respiratory infections (URIs) such as colds (rhinoviruses) and influenza. 
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Whereas some studies have supported its use in this capacity [15-19], others have discounted 
it [20-24], Most of the documented improvements regard faster symptoms resolution. Little 
is known about the possible mechanisms from a clinical standpoint. In one study, humans 
taking E. purpurea exhibit augmented numbers of circulating macrophages, natural killer 
cells, and neutrophils, and diminished neutrophil superoxide production [16]. Humans may 
respond differently to Echinacea based on age: in children, Echinacea does not help treat 
URIs and is associated with increased risk of rash [25], but decreases the risk of secondary 
infections [26]. Use of Echinacea for prevention of experimentally induced colds in adults 
has also been investigated with disappointing results [27, 28]. 
In vivo studies exploring the anti-inflammatory abilities of Echinacea have been 
restricted to animal models. Rodent studies have confirmed both anti-inflammatory and 
wound-healing benefits from Echinacea supplements applied topically [29, 30]. In one study 
of cultured human bronchial epithelial cells, rhinovirus-infected cells produced a battery of 
pro-inflammatory cytokines, but addition of Echinacea to these cultures resulted in decreased 
chemokine production [31]. The potential utility for Echinacea in human dermatitides has 
been suggested [32]. 
Echinacea may also exhibit other potentially medicinally useful properties. The 
following types of activities have also been documented from Echinacea extracts: 
antiapoptotic [33], antioxidant [34-37], antimicrobial [38], antiviral [39], and insecticidal [37, 
40]. Echinacea supplementation has been linked to increased longevity in mice [41]. 
Clearly, Echinacea harbors medicinal properties that seem to substantiate both 
traditional and contemporary uses for the genus, but these are inconsistent between studies 
and poorly characterized. Subsequent sections will examine how factors such as 
phytochemical variation, species selection, and extract type may partially explain the 
discrepancies in the scientific literature. In the next section, we will examine the effects of 
Echinacea on specific immune parameters. 
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Immunomodulatory activities 
Many and varied immunomodulatory properties have been documented from 
Echinacea spp. preparations, using both in vitro and in vivo models from animals and 
humans. Here we provide a broad overview of these properties. The effects of specific 
bioactive compounds from Echinacea on particular immune parameters is discussed below 
and provides supplementary information to this section; further, each of the experimental 
chapters in this dissertation (Chapter 2-6) provide additional reviews of Echinacea 
immunomodulatory properties in their introductions and discussions. 
Of the two main branches of immunity, Echinacea supplements appear to act more 
strongly on innate aspects (such as macrophages and inflammation) versus adaptive aspects 
(such as B cells, T cells, and antibody). Both in vitro and in vivo studies suggest Echinacea 
has strong effects on macrophages, natural killer cells, and neutrophils by increasing 
circulating numbers [16, 41-43]; enhancing proliferation [44]; enhancing phagocytosis [45, 
46], cytotoxicity (including against tumors) [44, 47] or conjugation/target lysis [48]; or 
modulating cytokine (i.e., IL-1, TNF-a) and reactive oxygen species production [16,46, 49]. 
Some effects on adaptive immunity-associated parameters (such as B cells and T 
cells) have been documented. The effects of Echinacea on B cell function (inferred from 
antibody production) seem to vary by route of administration across in vivo studies. Rats fed 
Echinacea via drinking water or gavage produce significantly more antibody in response to 
antigen [50, 51], but peritoneal injection of Echinacea to mice reduces IgG and IgM titers 
[34]. Echinacea can stimulate B cells and T cells to proliferate [52, 53]. T cells produce 
higher interferon-y levels [53]. Mice fed Echinacea with peanut butter exhibited higher 
circulating IL-2 levels compared to controls, supposedly produced by T cells [43]. Yet these 
improvements in B cell or T cell function are often linked to enhanced activity of 
macrophages, which are important stimulators of B cells and T cells [34]. 
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Phytochemistry 
Several compounds have been identified from Echinacea that may harbor 
immunomodulatory properties, based on preliminary investigations. These are divided into 
three widely recognized classes: alkamides, caffeic acid derivatives (phenylpropanoids), and 
polysaccharides [13, 54], 
Compared to the other classes of compounds, Echinacea polysaccharides (such as 
arabinogalactans, fructans, and pectic polysaccharides) have received the most scientific 
attention as regards their immunomodulatory properties. Overall, Echinacea polysaccharides 
appear to influence aspects of innate immunity moreso than adaptive immunity. In vitro, 
polysaccharides have been shown to stimulate macrophage production of several cytokines 
(IFN-p2, IL-1, IL-6, IL-10, and TNF-a) [55-57] and reactive oxygen species [58, 59]. 
Polysaccharides can activate complement [60] and may enhance B cell [59] and T cell [55] 
proliferation, but no other effects on these cell types have been documented. Some 
researchers have proposed that polysaccharides may not pass through the intestines into 
circulation without modification [61]. 
In vivo, Echinacea polysaccharides fed to immunosuppressed mice improved survival 
against both granulocyte- and macrophage-dependent pathogens, enhanced granulocyte 
proliferation in the bone marrow and spleen, and induced a quicker influx of granulocytes 
into the bloodstream following infection [57, 58]. Similar properties, such as changes in 
circulating leukocytes and induction of C-reactive protein, were observed upon intravenous 
administration of polysaccharides to humans [62]. Rodent studies using in vivo 
inflammatory models suggest these polysaccharides may harbor anti-inflammatory effects 
[29, 63, 64]. 
Alkamides may harbor anti-inflammatory activities through their inhibitory effects on 
macrophages [65] or cyclooxygenase pathways [37, 66]. Both alkamides and alkylamides 
may interact with cannabinoid receptors, thereby modulating immune parameters such as 
TNF-a mRNA production [67, 68]. Alkylamides may enhance macrophage function by 
increasing phagocytic abilities and production of TNF-a and nitric oxide [69]. 
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Bioavailability studies have suggested that alkamides reach the bloodstream without being 
modified by the digestive process [70, 71]. 
The immunomodulatory properties of the polyphenols, including caffeic acid 
derivatives (such as caftaric acid, cichoric acid, chlorogenic acid, cynarin, echinacoside, and 
verbascoside), anthocyanins, flavonoids, and phenolic acids, have received the least 
attention. They are known to scavenge oxygen radicals in chemical systems [72, 73]; this 
effect is enhanced when it is combined with alkamides and polysaccharides [35]. They 
demonstrate antihyaluronidase activity [74]; for echinacoside, this has been linked 
functionally to anti-inflammatory and wound-healing properties [29]. They also demonstrate 
antiviral effects in vitro [39]. Unlike alkamides, it's not believed these compounds are able 
to cross the intestinal barrier following ingestion [75]. 
Great variation exists in the abundance and distribution of these compounds. Within 
the genus, relative amounts differ by species [76] and may be influenced by ploidy level. 
Within a species, relative amounts differ by growth (habitat, weather, age at harvest) factors, 
and by subspecies [77-79], Within individuals, relative amounts vary by organ [13, 14, 79]. 
Roots seem to exhibit the highest levels of most of the bioactive molecules. 
Effects by species 
As demonstrated above, Echinacea species vary in their phytochemical profiles, 
possibly due to genetic differences as mentioned above. Thus, it is not surprising that they 
also differ in their immunomodulatory capabilities. Unfortunately, the overwhelming 
majority of cross-species research is solely phytochemical in nature and offers little in the 
way of comparing immunomodulatory properties. The bulk of the scientific literature 
focuses only on the three species employed commercially (Echinacea angustifolia, E. 
pallida, and E. purpurea) [13, 80]. There is currently not enough evidence to make broad 
statements about the immunomodulatory properties of one species compared to another, 
primarily because studies usually investigate only one species, and comparisons across 
studies are hampered by experimental differences. Only one study (on extract antiviral 
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activity) has endeavored to examine more than three species in a single investigation, and 
this was a purely biochemical study [39]. 
Effects by extraction process 
As different extraction procedures utilize different solvents, each removes different 
constituents from Echinacea material. Water extracts preferentially retain hydrophilic 
constituents, whereas alcohol extracts preferentially retain hydrophobic (lipophilic) 
constituents. In the context of the three major classes of Echinacea bioactive molecules: 
alkamides are best extracted by ethanol (or acetonitrile or hexane) solvents; caffeic acid 
derivatives/polyphenols may be extracted by alcohol or alcohol/water solvents depending on 
the particular molecule; and polysaccharides may be extracted by water or less effectively by 
alcohol/water solvents (as alcohol concentration increases, polysaccharide solubility 
decreases) [54]. 
Thus, the type of extract one is testing strongly impacts on the immunomodulatory 
properties that may be observed. Due to the emphasis placed on phytochemical profiling and 
the search for bioactive molecules, most scientific papers investigating the immunmodulatory 
properties of Echinacea spp. have employed extracts produced through sophisticated 
chemical isolation techniques. While ideal for biochemical studies, such extracts do not 
normally reflect the actual preparations that people consume. For example, these techniques 
typically use toxic solvents that result in extracts containing only a single molecule or group 
of related molecules. 
In contrast, consumer products are typically made from pressed juice, powdered plant 
parts, or alcohol or water extracts. Lay herbalism of this nature is becoming increasingly 
popular, and more Echinacea consumers are collecting plant material from the wild 
(wildcrafting) and generating their own water or water/alcohol extracts. Currently there is a 
remarkable paucity of data regarding the efficacy of extracts produced by lay herbalist 
techniques. Only one study has compared the differences between water and water/alcohol 
Echinacea extracts akin to those produced by lay herbalists on immune parameters. Using an 
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in vitro mouse splenocyte culture, they demonstrated that water extracts induced IL-6, IL-10, 
MlP- la, and TNF-a production, but alcohol/water extracts only augmented IL-10 and TNF-
a [49]. 
In addition to extract type, plant material processing methods (drying in particular) 
are also an important variable in determining the immunomodulatory capabilities of 
Echinacea preparations. Lay herbalists oftentimes engage in collection trips where they visit 
a particular region, collect useful material, then dry and store that material back at home 
(sometimes for years) for future use. Commercial manufacturers similarly harvest and then 
warehouse plants for up to several years (K. Kinds cher, personal communication). Optimal 
drying is necessary to prevent loss of active ingredients and microorganism contamination, 
but requires balancing temperature, time, and moisture content [81-83], For example, freeze-
drying Echinacea roots and flowers best preserves substances such as alkamides and caffeic 
acid derivatives compared to other methods, whereas air drying results in the biggest losses 
[84, 85]. 
EXPERIMENTAL DESIGN 
Rationale and approach 
It is clear from the above literature review that studies disagree about the 
immunomodulatory properties of Echinacea spp., possibly due to the confounding factors 
such as species selection, extraction technique, or storage condition. Unfortunately, specific 
information regarding these factors is rarely reported in the scientific literature, leaving us 
unable to evaluate whether or not these factors may explain some of the discrepancies seen 
across the published literature. 
The overarching purpose of the dissertation was to examine how different extract 
preparation factors (such as species selection, extraction techniques, and storage conditions) 
impacted the immunomodulatory capabilities of Echinacea spp. extracts. Our overarching 
hypothesis was that the immunomodulatory characteristics of Echinacea spp. extracts would 
be influenced by species selection, extraction technique, and extract storage conditions, 
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presumably due to phytochemical differences. We proffered that a controlled investigation 
of these factors may be beneficial in explaining some of the variability seen in previous 
investigations. For all of our assays, we studied variables associated with the immune 
response to upper respiratory infection, as the most common uses of Echinacea preparations 
in contemporary society are for the prevention or treatment of such infections. Our model 
was an in vitro human peripheral blood mononuclear cell (PBMC) culture system. We 
examined two main aspects of PBMC function in the model, proliferation and cytokine 
production. PBMC proliferation is an important response to infection, as it generates the 
necessary cellular militia for attacking a pathogen. Cytokines produced by PBMC are critical 
for orchestrating the total immune response to a pathogen, as they can stimulate immune 
cells to certain activities, direct immune cell traffic during an infection, or thwart the 
pathogen through direct effects. By focusing on immune parameters related to infection, we 
further proffered that our results might also be used to examine the purported validity of 
Echinacea spp. preparations used in the context of upper respiratory infection. 
To organize our efforts, we formulated three research foci that served as the 
foundation for the dissertation: (1) effects by species, (2) effects by extraction technique, and 
(3) effects by storage conditions. For each focus, we generated a general research question 
and one or more specific hypotheses that we could use to address the question 
experimentally. 
(1) Effects by species 
Our research question: What is the extent of phytomedicinal activity in the genus (i.e., 
which species harbor particular properties as compared to others)? We hypothesized that 
each individual Echinacea spp. would perform heterogeneously compared to other species 
across a broad panel of immune assays. An underlying assumption of this hypothesis is that 
a given individual species will perform in a somewhat consistent fashion between 
experiments, yielding a distinct "immunological profile" compared to others. 
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To address this hypothesis, we examined the PBMC proliferation-enhancing and 
cytokine-modulating properties of seven of the nine species of the genus: Echinacea 
angustifolia, E. pallida, E. paradoxa, E. purpurea, E. sanguinea, E. simulata, and E. 
tennesseensis. We were unable to obtain material from the other two species. By 
investigating the differences among species, we endeavored to: (a) address the lack of cross-
genus comparisons, and by corollary, better understand similarities and differences between 
the taxa; (b) provide important information for both commercial manufacturers and 
consumers of Echinacea spp. phytomedicines with regard to the potential utility of each 
species for particular medical conditions; and (c) possibly explain some of the pre-existing 
discrepancies in the scientific literature regarding the efficacy of Echinacea, as well as 
providing possible avenues for future investigation. 
(2) Effects by extraction techniques 
Our research question: Are lay herbalist techniques capable of producing extracts 
with immunomodulatory properties? Within this question, there were two separate aspects of 
lay herbalist methods that we wanted to explore: differences in extraction techniques 
themselves, but also differences in extracts produced from fresh versus dry material. 
Therefore, within this research focus we generated two hypotheses to address each of these 
two aspects separately. 
First, we hypothesized that both infusions and tinctures produced using lay herbalist 
methods would be efficacious in modulating some of the immune parameters in our model, 
but that the two extract types would produce effects distinct from one another as they each 
remove a different panel of biochemicals. Infusions are prepared by steeping plant material 
in water, either cold or hot (but not boiling), and are good for extracting hydrophilic 
constituents. Tinctures are prepared by steeping plant material in a combination of alcohol 
and water (we used 50% ethanol, 50% water), and are good for extracting both hydrophobic 
and hydrophilic constituents. We generated extracts using techniques similar to those used 
by lay herbalists or other individual consumers preparing their own Echinacea spp. 
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phytomedicines in domestic contexts, using both fresh and dried plant material. While we 
attempted to replicate lay herbalist methods as closely as possible, we did so under controlled 
laboratory conditions. This allowed us to control for such confounding factors as: 
consistency of measurements of plant materials and extract solvents; consistency of 
temperatures and steeping times during extract preparation; and issues of sterility or 
contamination through glassware or other tools used in the extract preparation and storage 
processes. 
Second, we hypothesized that drying the plant material for over a year would result in 
a complete loss of immunomodulatory activity, possibly due to degeneration of bioactive 
molecules. To address this, we harvested and stored root material in a climate-controlled 
facility for one and one-half years. Following storage, roots were processed into infusions 
and then tested in PBMC proliferation and cytokine production assays. 
By investigating the efficacy of lay herbalist techniques, we hoped to: (a) validate or 
refute the potential utility of these techniques to produced extracts with immunomodulatory 
properties; (b) compare differences in immunomodulatory properties between infusions and 
tinctures; (c) ascertain the effects of long-term drying on Echinacea phytomedicinal 
properties; (d) provide practical information to consumers and manufacturers about 
extraction technique; and (e) possibly explain some of the pre-existing discrepancies in the 
scientific literature regarding the efficacy of Echinacea, as well as providing possible 
avenues for future investigation. 
(3) Effects by storage conditions 
Our research question: How do different extract storage conditions, including those 
employed by both lay herbalists and scientific investigators, influence extract 
immunomodulatory activity? Within this question, there were two different aspects of 
storage that we wanted to consider—temperature and time. Therefore, within this research 
focus we generated two hypotheses to address each of these two aspects separately. To 
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examine differences in extract storage practices, we divided stock extracts into separate 
aliquots for storage at different temperatures and/or different lengths of time. 
First, we hypothesized that aliquots stored at different temperatures would exhibit 
heterogenous immunomodulatory activities in our model. We examined three different 
storage temperatures: 4°C (similar to refrigerator temperatures and analogous to conditions 
under which lay herbalists sometimes store Echinacea spp. preparations), -20°C (the standard 
storage temperature for laboratory extracts), and -80°C (a colder temperature than normally 
used, and possible alternative for enhancing the stability of extracts). 
Second, we hypothesized that aliquots stored for longer lengths of time would exhibit 
reduced immunomodulatory activity as compared to aliquots stored for shorter lengths of 
time. We examined three different lengths of time: four days at 4°C (representing the 
maximum time span that most lay herbalists retain Echinacea spp. extracts at refrigerator 
temperatures), one month at -20°C and -80°C (to examine the effects of short-term storage 
under laboratory conditions), and two years at -20°C (to examine the effects of long-term 
storage under laboratory conditions). 
By investigating the differences between storage conditions, we hoped to: (a) 
determine the effects of storage temperature on the immunomodulatory properties of 
extracts; (b) determine the effects of storage time on the immunomodulatory properties of 
extracts; (c) provide practical information to both consumers and lay and commercial 
manufacturers about the effects of these conditions on the potential performance of extracts; 
and (d) possibly explain some of the pre-existing discrepancies in the scientific literature 
regarding the efficacy of Echinacea, as well as providing possible avenues for future 
investigation. 
DISSERTATION ORGANIZATION 
This dissertation is organized in seven chapters, five of which represent original 
research papers. Chapter 1 has provided as a general introduction to the five papers and 
gives background information on the biology and phytomedicinal uses of the genus 
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Echinacea, outstanding research questions in the field, and the impetus for the dissertation 
projects. Chapters 2-6 represent the five original research papers as submitted to their 
respective journals. Each paper was designed to address some or all of the three specific 
research foci outlined in the previous section. The papers are organized to reflect continuity 
of experimental thought and are not presented in their chronological sequence. 
In Chapter 2, we examined the immunomodulatory properties of three different 
extract types (50% ethanol tincture, cold water infusion, and hot water infusion) prepared 
from five different species of Echinacea; further, we compared these properties at both one 
and four days post-extraction. Author contributions were as follows: DSS designed research; 
DSS, DAM, JMA, and JAJ performed research; JEC contributed reagents/analytical tools; 
DSS, MSK, and MLK analyzed data; and DSS and MLK wrote the paper. 
In Chapter 3, we explored whether Echinacea spp. roots from seven different species 
dried for sixteen months still retained cytokine-modulating properties when examined in an 
in vitro older human adult model of influenza vaccination. DSS and MLK designed research, 
analyzed data, and wrote the paper; and DSS, GNF, and DNK performed research. 
In Chapter 4, we explored whether Echinacea spp. root tinctures stored for two years 
under standard laboratory freezing conditions still harbored immunomodulatory properties in 
two young human adult models, with one subject pool undergoing influenza vaccination and 
the other group serving as unvaccinated controls. DAM and DSS designed research; DAM, 
FM, and DSS performed research; and DAM, MLK, and DSS analyzed data and wrote the 
paper. 
In Chapter 5, we initiated an in-depth exploration of the phytomedicinal properties of 
the federally endangered Echinacea tennesseensis as little is known about this species. DSS 
designed research; DSS, DAM, GNF, and ZZ performed research; JEC contributed 
reagents/analytical tools; and DSS and MLK analyzed data and wrote the paper. 
In Chapter 6, we collected our results from Chapters 2-5 and explored what they 
could tell us about the phytomedicinal activities of the genus Echinacea overall, with an 
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emphasis on species' similarities or differences. DSS designed and performed research; LEF 
and JFW analyzed data; and DSS and MLK wrote the paper. 
Chapter 7 provides general conclusions from a consideration of the five experimental 
chapters. The significance of the results is discussed. Additionally, it suggests some avenues 
for future research projects related to these topics. 
Following the main body of the dissertation are a series of appendices highlighting 
other research work I performed during my tenure as a PhD student at Iowa State University. 
For each, I give complete citation information as well as abstracts (when possible). 
Appendix A highlights other work done in immunology, whereas Appendix B showcases 
work done in other fields (primarily botany). 
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CHAPTER 2. CHANGES IN IMMUNOMODULATORY PROPERTIES OF 
ECHINACEA SPP. ROOT INFUSIONS AND TINCTURES STORED AT 4°C FOR 
FOUR DAYS 
A paper published in Clinica Chimica Acta 
David S. Senchina,2,3 Dustin A. McCann,3 Jessica M. Asp,4 Jack A. Johnson,3 
Joan E. Cunnick,2,5 Mark S. Kaiser,6 Marian L. Kohut2,3'7 
ABSTRACT 
BACKGROUND: Phytomedicinal preparations from members of the genus 
Echinacea are popular worldwide and frequently used to treat upper respiratory infections. 
With the increasing popularity of herbal medicines, many people are making their own 
Echinacea extracts at home and storing them at refrigerator (4°C) temperatures. We tested 
the hypothesis that Echinacea extracts made using homemade methods change in 
immunomodulatory efficacy with storage at 4°C over a 4-day period. METHODS: Three 
extract types (50% ethanol tincture, cold water infusion, hot water infusion) from 5 different 
species (E. angustifolia, E. pallida, E. purpurea, E. sanguinea, E. tennesseensis) were 
prepared. Four in vitro immune assays (monocyte secretion of TNF-a, IL-10, and IL-12; and 
peripheral blood mononuclear cell proliferation) using human blood were employed to test 
extract efficacy at days 1 and 4 post-extraction. Two statistical analyses, traditional ANOVA 
and several statistical models that account for endotoxin effects, were employed. RESULTS: 
Endotoxin was found to significantly impact immune outcomes only in 4-day old cold water 
infusions and not in all assays. Extracts showed the greatest stimulation in TNF-a assays. 
1 Reprinted from Clinica Chimica Acta, 355(1-2), Senchina DS, McCann DA, Asp JM, Johnson J A, Cunnick 
JE, Kasiser MS, Kohut ML, "Changes in immunomodulatory properties of Echinacea spp. root infusions and 
tinctures stored at 4°C for four days", pp. 67-82, copyright (2005), with permission from Elsevier. 
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6 Department of Statistics, Iowa State University 
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By extract type, 50% ethanol tinctures produced the most immune stimulation. By species, 
extracts from E. angustifolia extracts were the most efficacious in our assays; extracts from 
E. sanguinea showed the least activity overall. CONCLUSIONS: Taken together, these 
results suggest that: (1) homemade Echinacea extracts are efficacious in modulating immune 
cell activity in vitro but that their properties change with time during storage at 4°C; and (2) 
endotoxin effects from extracts may be important considerations in the analysis of 
immunobiological data. 
INTRODUCTION 
Medicines derived from plants (phytomedicines) are becoming increasingly popular 
as alternative therapies to traditional Western medicine [1], Echinacea use in the US has 
burgeoned since the 1980s to where it is now one of the top-selling phytomedicines [2, 3], 
As a medicinal supplement, Echinacea is best known for its abilities to help individuals 
prevent or minimize symptoms associated with upper respiratory infections (URIs) [4-7]. 
There is some disagreement among researchers regarding Echinacea's effectiveness. Studies 
examining human adults and their responses to various URIs have both supported [8-12] and 
refuted [13-17] its efficacy in this capacity. Echinacea has not demonstrated effectiveness in 
children [18]. 
The molecular mechanisms that Echinacea employs to exert its effects are currently 
under investigation [19,20]. Studies have shown numerous and varied immunomodulatory 
properties of Echinacea in a variety of animal models both in vitro and in vivo [1, 7]; we 
review here only those most germane to this paper. Experiments have demonstrated that 
Echinacea can modulate production of specific cytokines from human [21-24] and rodent 
[25-33] macrophages and peripheral blood mononuclear cells in vitro and in vivo. Further, it 
may: stimulate proliferation of peripheral blood mononuclear cells (PBMC); increase the 
number of circulating lymphocytes and monocytes; and increase the percentage of spleen NK 
cells [26, 31, 34, 35]. From a review of the literature, it appears that cells of the innate 
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immune system, frequently monocytes and macrophages, are the primary cellular responders 
to Echinacea extracts [4], 
The effect of Echinacea extracts on T-cell function has not been examined 
extensively. In response to viral infection, antigen-specific T-cells proliferate, secrete 
cytokines, and destroy virally infected cells via T-cell-mediated cytotoxicity. Echinacea 
extracts have been used by the public to enhance the clearance of viral infection and it is 
possible that the potential benefits of Echinacea involve T-cells. Macrophages are also 
important as a first line of defense against viral infection. Macrophage and/or monocyte 
function may be altered by Echinacea (21), and as these cells become activated, TNF-a 
secretion typically increases. TNF-a secretion can be used as a marker of macrophage 
activation. The IL-10 secreted by monocyte/macrophages may have anti-inflammatory 
properties and/or enhance B cell fonction, and IL-12 release can alter the Th1/Th2 
(macrophage- vs. B cell-stimulating) cytokine balance in response to infection. However, 
data regarding the effect of Echinacea on IL-10 or IL-12 production in human cells is rather 
limited. 
Many individuals choose to make their own Echinacea preparations from wildcrafted 
(field) or cultivated material for a variety of reasons. Unlike laboratory scientists, lay 
herbalists are limited in the types of extracts they may prepare. Due to their ease of 
preparation, infusions (steeping) and tinctures in alcohol, water, or a combination are 
frequently employed, with the products being used fresh or stored at refrigerator (4°C) 
temperatures. Despite the increasing practice of lay herbalism, the overwhelming majority of 
research has focused on extracts prepared in scientific laboratories or large-scale commercial 
facilities. 
In this study, we tested the hypothesis that Echinacea extracts from several species 
would exhibit a change in their in vitro immunomodulatory properties over a 4-day period 
when stored at 4°C. Three different types of infusions (50% ethanol, cold water, hot water) 
from 5 different species (E. angustifolia, E. pallida, E. purpurea, E. sanguinea, E. 
tennesseensis) were prepared and tested at Days 1 and 4 post-extraction for their ability to 
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enhance PBMC proliferation and monocyte production of TNF-a, IL-10, and IL-12 by 
human PBMC cultured in vitro. 
MATERIALS AND METHODS 
Plant sampling 
Three-year-old plant specimens grown from seed in outdoor fields were obtained 
from the USD A North Central Regional Plant Introduction Station (Ames, Iowa) in October 
2003. Five species were collected: Echinacea angustifolia var. angustifolia Ames 24994 
(ANG); E. pallida PI 631256 (PAL); E. purpurea (unknown parentage; PUR); E. sanguinea 
Ames 23879 (SAN); and E. tennesseensis PI 631250 (TEN). ANG, PAL, and PUR were 
chosen due to their widespread use in herbal preparations and scientific studies of Echinacea. 
SAN and TEN were selected as nothing is known of their medicinal properties. Voucher 
specimens for each plant used have been filed in the Ada Hayden Herbarium, Iowa State 
University (Ames, Iowa; ISC 435974—435980). Roots were processed into extracts no more 
than 2.5 hours following harvest. 
Extract preparation 
Methods for the preparation of Echinacea infusions vary by steeping time as well as 
by plant:solvent ratios in the popular literature. We chose an average steeping time of 20 
minutes and an average plant: solvent ratio of 1 part plant to 9 parts solvent. All equipment 
used was sterile from the manufacturer and/or autoclaved. Roots were diced using a surgical 
scalpel. Two grams of minced root was added to 18 mL of solvent for each extract. Three 
infusions were prepared for each species: (a) a room-temperature alcohol infusion of 50% 
ethanol/50% Nanopure water (abbreviated OH); (b) a room-temperature Nanopure water 
infusion (cold water infusion, or CW); and (c) a near-boiling Nanopure water infusion (hot 
water infusion, or HW). [In order to prepare an infusion, water is boiled and then added to 
plant material (thus extraction occurs as the water cools); the plant material is not boiled in 
the water (as in a decoction.)] Following 20 minutes of steeping, extracts were filtered 
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through fine-meshed tulle, placed in glass scintillation vials, and stored at 4°C. Extracts will 
hereafter be referred to as an abbreviation of plant and extract type (e.g., ANG-OH is the 
alcohol infusion from E. angustifolia). 
We chose to test the extracts at 1- and 4-days post-extraction based on extract 
stability as reported by the popular literature (for example, [36-39]). Such sources are likely 
to be used by lay herbalists looking for extract preparation recipes. According to these 
sources, infusions need to be prepared fresh daily or used within 3 days whereas tinctures 
may last on the order of years. By testing our extracts at 1- and 4-days post-extraction, we 
were able to test the supposition implied by the literature that infusions over 3 days old 
become "expired" (i.e., change in composition such that they are no longer efficacious). 
Endotoxin was measured using the Bio-Whitaker QCL 1000 kit (Cambridge, MA). 
Peripheral blood mononuclear cell (PBMC) isolation 
Human subjects protocols were filed and approved by the Institutional Review Board 
for Human Subjects. PBMC's were isolated from healthy human donors and separated over 
Ficoll-Paque plus (Amersham Pharmacia Biotech, Piscataway, NJ). Cells were counted and 
adjusted to a concentration of 1.0 x 106 cells/mL in AIM-V media (GIBCO/Invitrogen, 
Carlsbad, CA). Five donors were used per assay per extract per day. Due to experimenter 
error and/or limitations in the number of cells obtained from specific donors, the number of 
subjects whose data was used in statistical analysis and graphing was smaller (average n = 
4.0; range 3-5). 
Lymphocyte proliferation assay 
One hundred pL aliquots of cells were plated in 96-well round-bottom Costar plates 
with extract or control substance (media alone for water infusions and media + alcohol for 
ethanol tinctures) for 5 days under standard incubation conditions (37°C, 5% C02, in a 
humidified atmosphere). Each experiment was done in triplicate and the values averaged. 
Following incubation, Cell!iter (Promega, Madison, Wl) was added to each well and the 
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plates incubated for a further 3 hours before being read in plate reader (Bio-Rad, Hercules, 
CA) at 450 nm. 
Monocyte cytokine production 
One mL of cells was plated in 24-well flat-bottom Costar plates with extract or 
control substance (media alone for water infusions and media + alcohol for ethanol tinctures) 
for 24 hours under standard incubation conditions. Following incubation, supematants were 
collected and frozen at -20°C until assayed via ELISA (BD Biosciences Pharmingen, San 
Diego, CA). 
Traditional statistical analyses 
Effects by species and by extract type were determined using two-way ANOVA. An 
a-level of 0.05 for significance was assumed in all analyses. If a significant interaction 
between species and extract type was observed, follow-up one-way ANOVA tests were used. 
The extract(s) were compared to the appropriate control (media or media plus alcohol) 
separately for each of the plant species. Bivariate correlations between extract endotoxin 
levels and experiment results were determined in SPSS (Statistical Product and Service 
Solutions; Chicago, IL). 
Statistical analyses from model selection 
Exploratory data analysis indicated that potential effects on responses such as 
lymphocyte proliferation, TNF-a production, and IL-10 production at Day 4 did not follow 
simple patterns caused by homogeneous effects due to species or extraction procedure. 
Instead, there appeared to be some effect due to endotoxin levels but, again, this effect did 
not appear to be uniform across extractions (see results), precluding the use of standard 
analyses of covariance. In order to determine whether different species of Echinacea and/or 
different extracts prepared from Echinacea have immunomodulatory effects, more 
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sophisticated statistical models were necessary to account for the potential confounding 
effects of endotoxin in the Echinacea preparations 
A model selection approach was needed to determine which effects might be 
influencing observed responses under which situations. To accomplish this, let Yt\i = 1 
denote the observed responses for observation z, which indexes an arbitrary ordering of the 
combination of extraction, species, and subject. Let St denote species and E, extraction for 
these same observations, and let x, denote the endotoxin level for the observations. Any 
number of linear models can be formulated under this notation. For example, a model having 
an effect for all extractions and endotoxin would be written as: 
% = = OH) + = HW) + = CW) + 
where c, ~ iidN(0,1 ) for i = 1and 1(A) is the indicator function, taking a value of 1 if the 
argument A is true and 0 otherwise. Similarly, a model having effects only for species PAL 
and an endotoxin effect, but only for the cold water extractions, would be written as, 
Y, = /?o + Pi I(Sj = PAL) + yxj{Ei = CW) + as/. 
A series of models were fitted for each response using a consistent parameter notation in 
which ,/?5 denote the effects of the five species ANG, PAL, PUR, SAN, and TEN, 
respectively; a\, a2, denote the effects of the three extractions OH, CW, and HW 
respectively; and 7 denotes the effect of endotoxin level. The overall parameter /% was used 
in models for which only certain species of extractions were included to represent the overall 
mean response. 
Nested models were compared in a sequential fashion using a standard general linear 
test procedure to select a "final" model for each response. The final model was chosen in 
such a way that it was preferred to both any of the next most complex models and any of the 
next most simple models. For example, the final model for the lymphocyte proliferation 
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response turned out to be a model with no effects other than endotoxin in the cold water 
extractions only, 
Yi = f5{) + yxJiE, = CW) + 
This model was chosen (using general linear test procedures) over more complex models 
having species effects and endotoxin for cold water extractions only, extraction effects and 
endotoxin effects for cold extractions only, only endotoxin effects but for all observations, 
and for the simpler model having no effects (constant only). 
Standard diagnostic procedures, such as plots of standardized residuals against fitted 
values, were used to examine the appropriateness of final models selected for description of 
the relevant data sets. Such procedures were conducted individually for responses of 
lymphocyte proliferation and TNF-a and IL-10 production. 
RESULTS 
Final model selection 
Figure 2-2-1 presents endotoxin level against mean lymphocyte response by extract 
type for each of the four assays at both Day 1 and Day 4. Figure 2-2-1 suggests that 
endotoxin may produce an elevated response for cold water extractions but perhaps not for 
the other extractions, and only at Day 4. These suspicions were further corroborated when 
numerical correlation analyses were performed and significant correlations were found in 
CW extracts but only at Day 4 for lymphocyte proliferation, IL-10, and TNF-a assays (Table 
2-2-1). Thus, fitted model selection procedures as described in methods were needed to 
explain endotoxin influences in these instances because they are not captured by two-way 
ANOVA, which considers only species by extract type effects. In this way individual models 
were developed for analysis of Day 4 IL-10, Day 4 TNF-a, and Day 4 lymphocyte 
proliferation results. Final models chosen, as well as estimates of specific parameters in each 
model, are displayed in Table 2-2. 
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PBMC proliferation 
Human peripheral blood mononuclear cells (PBMC) were incubated in vitro with 
Echinacea extract or control for 5 days and proliferation was assessed via CellTiter 
(Promega, Madison, WI). Results are shown in Figure 2-2. Optical density is an indirect 
measure of proliferation; therefore, higher values of optical density indicate greater PBMC 
proliferation. 
At Day 1 post-extraction, two-way ANOVA revealed no main effects of extract type 
or species, suggesting that none of the extracts significantly altered PBMC proliferation 
(Figure 2-2a). For the data at Day 4 post-extraction, we found that all differences among 
species or extract types could be explained entirely by endotoxin in the CW extracts (Figure 
2-2b and Table 2-2). Thus, no differences were seen between different species or extract 
types and the results from the model in Table 2-2 suggest that any differences in PBMC 
proliferation are related to the amount of endotoxin in the extract. 
Monocyte cytokine production 
Human lymphocytes were incubated in vitro with Echinacea extract or control for 24 
hours. Supernatants were collected and assessed via ELISA for production of the pro­
inflammatory cytokine TNF-a (Figure 2-3) and the anti-inflammatory cytokines IL-10 
(Figure 2-4) and IL-12 (Figure 2-5). 
TNF- a Production 
At Day 1, two-way ANOVA revealed a significant main effect of extract type 
(p=0.001) and a significant extract-by-species interaction (p=0.013; Figure 2-3a). According 
to main effect tests, CW and OH extracts stimulated significantly greater TNF-a production 
than HW extracts. Furthermore, a main effect of species suggested that PUR extracts 
produced significantly higher levels of TNF-a than ANG or PAL extracts, whereas ANG, 
PAL, and PUR extracts stimulated higher TNF-a levels than both SAN and TEN 
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preparations. Also, cells stimulated with ANG, PAL, and PUR extracts produced 
significantly greater amounts of TNF-a than controls (no Echinacea). One-way ANOVA 
follow-up tests were used to compare the effect of each species within each extract type. 
Among OH extracts, a species effect was found (p<0.001) such that the addition of PUR to 
cell cultures resulted in significantly greater levels of TNF-a than all other species, followed 
by ANG and PAL. SAN, TEN, and control (no Echinacea) trials were significantly lower 
than ANG and PUR. Within CW extracts a species effect was found (p<0.001) such that 
PUR and PAL > ANG, SAN, and TEN, and ANG > SAN. However, only PAL and PUR 
were significantly greater than control (no Echinacea). A comparison of the HW extracts 
again showed an effect of species (p=0.04) such that PUR > ANG, SAN, and TEN, but not 
different from PAL; importantly, only PUR was greater than control (no Echinacea). Taken 
together, the results generally suggest that PAL and PUR had the greatest effects on in vitro 
TNF-a production, but if an extract had been prepared with alcohol rather than water, ANG 
also augment TNF-a production. 
At Day 4 post-extraction, after accounting for the endotoxin present in CW extracts 
using the model developed in Table 2-2, some significant differences were observed (Figure 
2-3b). The data suggested that OH extracts prompted reduced responses as compared to 
other extract types. Also, extracts from TEN increased TNF-a production as compared to all 
other species and control (no Echinacea) whereas PAL extracts exhibited reduced TNF-a 
production as compared to all other species and control (no Echinacea). 
IL-10 Production 
When a two-way ANOVA was employed to examine effects by extract type at Day 1 
(Figure 2-4a), a main effect of extract was observed (CW > HW > OH; p^O.OOl ); a main 
effect of species was found (ANG > PAL, PUR, SAN, and TEN p<0.001); and a significant 
extract-by-species interaction was observed (p<0.001). A follow-up one-way ANOVA was 
used to compare the differences between species for each extract type. A comparison of the 
OH extracts indicated that only the addition of ANG to cell cultures, but not any of the other 
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species, resulted in greater IL-10 production than control (no Echinacea). Among the CW 
extracts, the addition of ANG to cultures resulted in greater IL-10 production as compared to 
all other species (ANG > PAL, PUR, SAN, TEN, and control [no Echinacea]-, p<0.001). 
Within the HW extracts, both ANG and PUR enhanced IL-10 production when compared to 
SAN or control (no Echinacea). Thus, the results tend to suggest that ANG has the strongest 
effect on IL-10 production unless the extract was prepared with HW. Under HW methods, 
both ANG and PUR increase in vitro IL-10 production. 
At Day 4 post-extraction, after accounting for the endotoxin in CW extracts, several 
significant differences were noted (Figure 2-4b and Table 2-2). The data suggested that OH 
extracts promoted increased IL-10 production. Results were also suggestive that both PUR 
and SAN extracts tended to decrease IL-10 responses relative to other species and control (no 
Echinacea). 
IL-12 Production 
At Day 1 post-extraction, two-way ANOVA revealed significant differences in the 
extract type comparisons (significant main effect of extract; p=0.004) such that OH- and 
CW-treated cells produced significantly greater IL-12 than HW-treated cells. With regard to 
species, a main effect was also observed (ANG and PAL > PUR, SAN, TEN, and control [no 
Echinacea]; p=0.006). A significant extract-by-species interaction also observed and 
therefore the follow-up one-way ANOVA was used to examine species differences across 
extract types. In a comparison of OH extracts, only the addition of ANG to cell cultures 
resulted in significantly (p=0.005) greater IL-12 production than control (no Echinacea). 
However, among the CW extracts, PAL-stimulated cells produced significantly greater 
(p=0.011) IL-12 than the control (no Echinacea) cells, and ANG showed a trend towards 
greater IL-12 production (p=0.062). Interestingly, the comparison of HW extracts suggested 
that none of the species enhanced IL-12 production. In summary, extract preparation 
appeared to be an important factor in determining whether Echinacea altered IL-12 in our 
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preparations at Day 1. ANG showed elevated IL-12 production when prepared in OH or 
CW, whereas PAL appeared to have an effect only when a CW preparation was used. 
Unlike our analyses for the other three immune parameters, we were able to use the 
two-way ANOVA procedure to analyze IL-12 production at Day 4 because endotoxin did not 
appear to influence IL-12 production. The results of the two-way ANOVA revealed a main 
effect of extract (CW > HW > OH; pO.OOl) and a main effect of species (TEN > ANG, 
PAL, PUR, SAN, and control [no Echinacea]; p<0.001). However, a significant extract-by-
species interaction was observed (p=0.001) and therefore follow-up one-way ANOVA 
analyses were performed to determine how different species performed across extract types. 
The results showed that among OH extracts, none of the Echinacea species showed 
significant stimulation of IL-12 production; in fact, PUR and TEN decreased IL-12 as 
compared to control (no Echinacea). In contrast, within the CW extracts, IL-12 production 
from cells cultured with PUR and TEN was significantly greater than control (no Echinacea; 
p<0.018). Similarly, with HW extracts, TEN also demonstrated the greatest effect on IL-12 
production such than TEN > ANG, PAL, PUR, SAN, and control (no Echinacea; p=0.001). 
Taken together, these results suggest that TEN appears to have the greatest effect on IL-12 
production when extracts are stored for a four-day period; however, the OH extracts from 
TEN actually suppress IL-12 production. 
DISCUSSION 
In this study, we investigated the effects of Echinacea extracts on several immune 
parameters in vitro using three different extraction methods (OH, CW, and HW) from five 
different species (ANG, PAL, PUR, SAN, and TEN). These extracts were stored at 
refrigerator temperature (4°C), similar to storage conditions that a lay herbalist might 
employ, and tested for immunoefficacy at both Day 1 and Day 4 post-extraction. Previously, 
no results have been reported regarding time effects on extract efficacy. We observed that 
the immunostimulatory properties of extracts did change over the time period tested (Figures 
2-5). 
36 
Importantly, during preliminary statistical analyses of the data, concerns arose over 
the potential confounding effects of endotoxin levels in the extracts (Figure 2-2-1 and Table 
2-2-1). Endotoxin derives from the outer membrane of certain bacteria and has a direct 
immune stimulatory effect. The presence of endotoxin is not a product of the extraction 
process but derives from extract contamination - bacteria growing on the plant at the time of 
harvest become inadvertently incorporated into the extracts. Endotoxin contamination is 
expected to occur, but the effects of the extraction processes themselves on endotoxin or the 
bacteria that produce it are unknown. Therefore, the concern was that the immune 
modulation we were observing might have be due more to endotoxin than Echinacea 
compounds themselves. One team has recently demonstrated that Echinacea preparations 
may act on innate immune system cells mechanistically similarly to LPS [19]. Many in vitro 
studies have not reported endotoxin levels from their extracts, but the importance of 
endotoxin effects in Echinacea extracts have been considered by some investigators [22,40]. 
Endotoxin is more of a concern for in vitro versus in vivo assays, because the gut typically 
excludes endotoxin from entering the bloodstream. 
In particular, endotoxin may have influenced the results seen in the CW extracts at 
Day 4, but not in any other extract type nor at any other time point. More sophisticated 
models of statistical analyses were thus developed to address whether endotoxin influenced 
the results observed (Table 2-2). These analyses strongly suggested that complex 
interactions were occurring between endotoxin and CW Day 4 extracts. These interactions 
were not simply due to absolute endotoxin levels: for instance, overall HW extracts had 
higher endotoxin levels than CW extracts (Figure 2-2-1), but endotoxin was not observed to 
significantly influence the results seen with HW extracts at Day 4. The main message 
delivered by these analyses is that endotoxin levels in CW extracts stored at 4°C did have a 
significant impact on our immune parameters by Day 4, and that the influence of endotoxin 
in such extracts must be taken into account when considering experimental outcomes. 
37 
PBMC proliferation 
None of the 15 extracts tested at Day 1 or Day 4 had a statistically significant effect 
on lymphocyte proliferation (Figure 2-2), even after accounting for endotoxin in CW 
extracts. T-cells are components of the adaptive (specific) immune system. However, most 
studies have shown that Echinacea affects members of the innate (nonspecific) immune 
system more regularly [4], Our results are thus consistent with those of other researchers 
who have demonstrated that extracts from Echinacea species have minimal effect on T-cell 
proliferation [4, 41]; however, Echinacea may stimulate macrophage which in turn drive T-
cell proliferation [42]. One study did show an enhancement of proliferation when 
Echinacea-derived arabinogalactan (a polysaccharide) was employed [33]. Although our 
results suggest that Echinacea extracts do not alter PBMC proliferation, it remains possible 
that other T-cell responses may be affected, such as findings from our data with IL-10 (a Th2 
cytokine). 
TNF- a production 
Among all 3 types of extracts (OH, CW, HW) only PUR-based extracts consistently 
increased production of TNF-a in vitro at Day 1 (Figure 2-3a). ANG also increased TNF-a, 
but only when prepared with OH, and PAL enhanced TNF-a production, but only when 
prepared with CW. At Day 4, after accounting for CW endotoxin effects, the data suggested 
that OH extracts and PAL extracts reduced whereas TEN increased TNF-a production 
(Figure 2-3b). It has previously been demonstrated that TNF-a production by monocytes or 
macrophages may be increased upon application of laboratory-derived Echinacea extracts in 
both human in vitro cultures [22, 23], rodent in vitro cultures [25, 29-33], and rodent in vivo 
models [27, 28]. Our results confirm and extend these findings for human peripheral blood 
mononuclear cell cultures and show that temporal factors may also influence extract 
properties. While TNF-a is an integral component to a healthy inflammatory reaction in 
response to viral or other infectious diseases [43], excess levels may be responsible for 
certain chronic inflammatory conditions such as rheumatoid arthritis [44] and inflammatory 
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bowel disorders [45]. Therefore, it appears that acute elevation of TNF-a may yield a more 
beneficial immune response to pathogens, but prolonged elevation can lead to certain chronic 
diseases and tissue or DNA [46] damage. In terms of clinical relevance, our observations are 
thus difficult to interpret. Echinacea-induced upregulation of TNF-a may have beneficial or 
deleterious effects depending on the in vivo context. 
IL-10 production 
Our results indicated that with all three types of extracts (OH, CW, HW), ANG 
stimulated IL-10 production at Day 1 (Figure 2-4a). However, PUR also increased IL-10 
production, but only from HW extracts. Surprisingly, the data suggested that the same PUR 
extracts inhibited IL-10 production at Day 4 along with SAN extracts (Figure 2-4b) after 
accounting for CW endotoxin effects. OH extracts overall might stimulate IL-10 production 
at Day 4 (Figure 2-4b). Thus it would appear that in the case of ANG and PUR extracts, Day 
1 extracts are potentially more beneficial than Day 4 extracts. Other investigators have 
previously shown that laboratory-derived Echinacea extracts can promote IL-10 production 
in human [22] and rodent [29, 31] lymphocyte cultures. Our results confirm and extend these 
findings for human lymphocyte cultures and show that temporal factors may influence 
extract abilities. Echinacea-induced augmentation of IL-10 could yield physiologically-
relevant benefits: for example, IL-10 is known for its anti-inflammatory properties and may 
play a role in the clearance of viral or other infectious disease, or IL-10 may respond as a Th2 
cytokine, thereby augmenting B cell response and subsequent antibody production [47, 48]. 
lL-12 production 
Interestingly, the plant species and extract type that enhanced IL-12 production at 
Day 1 (ANG in OH and CW, PAL in CW; Figure 2-5 a) were not the same as those that 
increased IL-12 production at Day 4 (TEN in CW and HW, PUR in CW; Figure 2-5b). At 
Day 4, OH extracts from PUR and TEN suppressed IL-12 production as compared to control 
(no Echinacea); there was also a trend in SAN-OH extracts in this direction. It is interesting 
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to note that the same species could have opposing effects on IL-12 production based on the 
type of extract. TEN-OH extracts diminished while TEN-CW and TEN-HW extracts 
enhanced IL-12 production. Similarly, PUR-OH extract decreased whereas PUR-CW extract 
increased IL-12 synthesis at Day 4. 
Previously, researchers have reported no effects of either alcohol or water laboratory-
derived Echinacea extracts to promote IL-12 production in rodent lymphocyte cultures [29]. 
Here we demonstrate that Echinacea extracts may harbor this capacity in regards to human 
lymphocyte cultures. Ech wacea-induced upregulation of IL-12 could yield physiologically-
relevant benefits: IL-12 is known to help promote a strong TrI (CD8+ or cytotoxic T-cell) 
response in reaction to viral infection, and increased levels of this cytokine could lead to 
more efficient viral clearance [49, 50]. 
Effects by species 
At Day 1, only extracts from ANG showed immunoenhancing properties in all of our 
cytokine assays. PAL showed enhancing activity with respect to TNF-a and IL-12, whereas 
PUR enhanced TNF-a and IL-10. Extracts from neither SAN nor TEN demonstrated these 
properties. From these preliminary findings, it thus seems that Echinacea angustifolia was 
the most efficacious species in the assays employed here, with E. pallida and E. purpurea 
exhibiting mild activity. In addition, TNF-a was the only cytokine whose production was 
enhanced in vitro by all 3 of these species. The trends from Day 4 are less clear; however, it 
appears that TEN increased cytokine production in 2 of the 3 cytokines measured (IL-12 and 
TNF-a, after accounting for endotoxin effects). 
Commercial preparations of Echinacea typically employ 3 species: E. angustifolia 
(multiple varieties), E. pallida, and E. purpurea [1,51]. This explains both why E. 
sanguinea and E. tennesseensis have been neglected in the scientific literature and why so 
much more is known about these three other species. Our results suggest that E. angustifolia 
was a more consistent enhancer of immune function in vitro than either E. pallida or E. 
purpurea. To the best of our knowledge, these studies constitute the first data on lymphocyte 
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proliferation and cytokine production by 2 species, E. sanguinea and E. tennesseensis. 
Regarding these two species, while we saw little activity in SAN extracts, TEN extracts did 
appear to have some immunoenhancing effects that only became apparent after 4 days of 
storage. Our results suggest that E. tennesseensis may warrant further phytomedicinal 
investigation. 
Effects by extract type 
Based on the number of species that demonstrated activity, OH extracts seemed to be 
the most capable of enhancing in vitro immune properties at Day 1, followed by CW and 
then HW extracts. No extract type significantly decreased any immune activities at Day 1. 
In contrast, at Day 4 OH extracts showed repressive activities in both the TNF-a and IL-12 
assays, no effect on lymphocyte proliferation, and a promoting effect only in the IL-10 assay. 
The only significant activity seen in CW and HW extracts at Day 4 was promotion of IL-12 
production. 
Alcohol and water extractions pull out chemically dissimilar constituents 
(hydrophobic and hydrophilic molecules in the case of the former; hydrophilic molecules in 
the latter). In previous studies, it has been shown that alcohol and water extracts can have 
contrasting effects; for example, it was shown that IL-6 production by rodent splenocyte 
cultures could be increased by water extracts but not by alcohol extracts [29]. As we 
observed effects from both alcohol- and water-derived extracts, our results may suggest that 
Echinacea contains both hydrophilic and hydrophobic molecules capable of stimulating 
immune response in human PBMC in vitro. Our results are consistent with those of other labs 
who have also reported immunomodulatory effects from both alcohol and water extraction 
methods [7, 25,29, 52]. 
Changes in activity with time 
In all of our assays, we witnessed a change in immunomodulatory activity of the 
extracts during 4 days of storage at 4°C. It might have been predicted that all extracts would 
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decrease in activity with time as chemical compounds naturally degraded, but this prediction 
was not borne out by our data. While there was a general pattern of decreasing activity with 
time in our T-cell proliferation assay (Figure 2-2), extracts variously increased or decreased 
in activity with time in all of our cytokine assays (Figures 3-5). These results suggest that 
Echinacea infusions made at home and stored in the refrigerator may yield different 
immunomodulatory effects over time. Further in vivo experimentation is necessary to test 
this hypothesis. It is also unclear to what degree Echinacea compounds in the extracts 
degraded over the course of the experiment and how this impacted our results. The behavior 
of bacteria in extracts during storage at 4°C is also uncertain. Additional biochemical 
analyses of changes in extract composition with time would help resolve these questions. 
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Table 2-1. Correlation between endotoxin levels in extracts and immunomodulatory activity. 
T-cell proliferation TNF-a IL-10 IL-12 
Day 1 Day 4 Day 1 Day 4 Day 1 Day 4 Day 1 Day 4 
All Extracts 03? 0.557 0.062 0.348 0.292 0.252 -0.385 0.154 
0.943 0.031+ 0.826 0.203 0.29 0.364 0.157 0.584 
OH Extracts -0.446 0.588 0.807 0.749 0.016 -0.399 -0.063 -0.705 
0.452 0.297 0.099 0.145 0.98 0.506 0.92 0.184 
CW Extracts 0.331 0.952* 0.614 0.871 0.161 0.886* -0.122 0.308 
0.586 0.013* 0.271 0.054 0.796 0.046* 0.845 0.614 
HW Extracts -0.316 0.221 0.145 0.852 0.831 -0.145 -0.255 -0.478 
0.604 0.721 0.816 0.067 0.082 0.816 0.679 0.455 
a The top value given in each comparison is the Pearson correlation coefficient; the bottom value given is the p 
value indicating statistical significance. * = Significant values. t = This value is not considered significant as 
the total contribution of significance comes solely from CW extracts and no contributions come from OH or 
HW extracts. 
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Table 2-2. Final models chosen for analysis of Day 4 IL-10, TNF-a, and lymphocyte 
proliferation results as discussed in the methods. 
Estimated values of... 
Parameters 
Po Pi Pi P3 A Ps ai y c? R2 
IL-10a'b 3.716 iïâ na -0.552 -0.687 na 0.626 1.378 0.939 0.592 
TNF-ac 0.425 na na na na na na 0.031 0.002 0.26 
Proliferation^ 4.255 na -0.713 na na 0.336 -0.754 1.021 0.359 0.799 
a The analyses for both IL-10 and TNF-a were conducted using log-transformed data. 
b Formula for IL-10: Y, = /% + /??/(.S', = PUR) + = SAN) + aJiE, = OH) + p:,I(E, = CW) + 
c Formula for TNF-a. Y, = + /3yI(Sl = PAL) + flsKS, = TEN) + a/KE, = OH) + pcJ^Ei = CW) + ere;. 
d Formula for proliferation: Y, =y% + yx,I{Ei e CW) + uSi. 
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Figure 2-1. Relationship between endotoxin level and cytokine production (TNF-a, IL-10, 
IL-12) or PBMC proliferation at both Day 1 and Day 4. Letters denote extract types: 
A-alcohol, C=cold water, H=hot water. Numbers denote species: 1 =E. angustifoiia, 2 =E. 
pallida, 3 =E. purpurea, 4=E. sanguinea, 5=E. tennesseensis. No endotoxin values were less 
than zero. 
50 
0.6 
med med jOH CW HWjfOH CW HW|jQH CW HWjjOH CW HW||QH CW HW) 
0H 
~ "" pal pur san ten ang 
•y- 0.6 
CW HW] med med OH CW HW 
Figure 2-2. Lymphocyte proliferation at Day 1 (a) and Day 4 (b). Optical impedance is an 
indirect measure of proliferation; higher values of optical impedance indicate greater PBMC 
proliferation. Media alone (med) is the appropriate control for comparison with the cold 
(CW) and hot water (HW) extracts; media supplemented with alcohol (med OH) is the 
appropriate control for comparison with the alcohol (OH) extracts. Significance varies by 
statistical measure used and is discussed in the text. Species abbreviations: ang=E. 
angustifolia, pal=E. pallida, pur=£. purpurea, san=£. sanguinea, ten=E. tennesseensis. 
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Figure 2-3. TNF-a production at Day 1 (a) and Day 4 (b). Media alone (med) is the 
appropriate control for comparison with the cold (CW) and hot water (HW) extracts; media 
supplemented with alcohol (med OH) is the appropriate control for comparison with the 
alcohol (OH) extracts. Significance varies by statistical measure used and is discussed in the 
text. Species abbreviations: ang=E. angustifolia, pal=E. pallida, pur=E. purpurea, san=E. 
sanguinea, ten=E. tennesseensis. 
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Figure 2-4. IL-10 production at Day 1 (a) and Day 4 (b). Media alone (med) is the 
appropriate control for comparison with the cold (CW) and hot water (HW) extracts; media 
supplemented with alcohol (med OH) is the appropriate control for comparison with the 
alcohol (OH) extracts. Significance varies by statistical measure used and is discussed in the 
text. Species abbreviations: ang-E. angustifolia, pal=E. pallida, pur=E. purpurea, san=E. 
sanguinea, ten=£. tennesseensis. 
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Figure 2-5. IL-12 production at Day 1 (a) and Day 4 (b). Media alone (med) is the 
appropriate control for comparison with the cold (CW) and hot water (HW) extracts; media 
supplemented with alcohol (med OH) is the appropriate control for comparison with the 
alcohol (OH) extracts. Significance varies by statistical measure used and is discussed in the 
text. Species abbreviations: ang=E. angustifolia, pal=£. pallida, pur=£. purpurea, san=E. 
sanguinea, ten=E. tennesseensis. 
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CHAPTER 3. YEAR-AND-A-HALF OLD, DRIED ECHINACEA SPP. ROOTS 
RETAIN CYTOKINE-MODULATING CAPABILITIES IN AN IN VITRO HUMAN 
OLDER ADULT MODEL OF INFLUENZA VACCINATION 
A paper submitted to Planta Medica1 
David S. Senchina,2,3 Lankun Wu,4 Gina N. Flinn,3 Del N. Konopka,3 Joe-Ann McCoy,6 
Mark P. Widrlechner, Eve S. Wurtele,4 Marian L. Kohut2,3,7 
ABSTRACT 
Alcohol tinctures prepared from aged Echinacea spp. are typically taken for 
preventing or treating upper respiratory infections, as they are purported to stimulate 
immunity in this context. The effects of long-term (> 1 year) drying on the capabilities of 
Echinacea spp. roots from mature individuals to modulate cytokine production are unknown. 
Using an older human adult model of influenza vaccination, we collected peripheral blood 
mononuclear cells from subjects 6 months post-vaccination and stimulated them in vitro with 
the two Type A influenza viruses contained in the trivalent 2004-2005 vaccine with a 50% 
alcohol tincture prepared from the roots of one of seven Echinacea species: E. angustifolia, 
E. pallida, E. paradoxa, E. purpurea, E. sanguinea, E. simulata, and E. tennesseensis. 
Before being processed into extracts, all roots had been dried for one and one half years. 
Cells were cultured for 48 hours; following incubation, supematants were collected and 
assayed for interleukin-2, interleukin-10, and interferon-y production, cytokines important in 
immune response to viral infection. Four species (E. angustifolia, E. purpurea, E. simulata, 
E. tennesseensis) augmented IL-10 production, diminished IL-2 production, and had no 
effect on IFN-y production. E. pallida suppressed production of all cytokines; E. paradoxa 
1 Submitted October 7, 2005; reviewers' comments received February 7, 2006. 
2 Immunobiology Program, Iowa State University 
3 Department of Health and Human Performance, Iowa State University 
4 Department of Ecology, Evolution, and Organismal Biology, Iowa State University 
5 Department of Genetics, Iowa State University 
6 USDA North Central Regional Plant Introduction Station, Ames, Iowa 
7 Gerontology Program, Iowa State University 
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and E. sanguinea behaved similar to E. pallida, although to a lesser extent. The results from 
these in vitro bioactivity assays indicate that Echinacea spp. roots dried for a year and a half 
maintain cytokine-modulating capacities. Our data support previous research and suggest 
that different Echinacea spp. extracts have different patterns of immune modulation; further, 
they suggest that certain species may be efficacious in the immune response to viral 
infection. 
INTRODUCTION 
The use of Echinacea spp. phytomedicinal preparations has grown in the past few 
decades [1, 2], Echinacea has documented immunomodulatory properties and is most 
frequently consumed to prevent or minimize symptoms from upper respiratory infections, 
although scientific studies regarding its efficacy in this capacity report dissimilar findings 
[3], Echinacea can modulate patterns of cytokine expression, as has been shown previously 
[4, 5], and this may increase resistance to infection. Some cytokines important in response to 
viral infection include interleukin-2 (IL-2; enhances T-helper cell function, important in 
adaptive immunity against many viruses), IL-10 (regulator of cytokine synthesis with anti­
inflammatory actions), and interferon-y (IFN-y, an antiviral cytokine). Although a well-
controlled clinical trial recently demonstrated that Echinacea angustifolia did not minimize 
viral load in response to rhinovirus challenge [6], it is possible that Echinacea spp. may alter 
cytokine expression in such a way as to reduce inflammation and associated symptoms. 
Just recently, excellent strides have been made to better understand the effects of 
drying on bioactive constituents of Echinacea roots. Both commercial manufacturers and lay 
herbalists commonly employ drying processes. The effects of commercial drying regimens 
(i.e., high temperatures and short drying times, sometimes involving techniques such as 
convection drying, freeze drying, or vacuum drying) on bioactive constituents of Echinacea 
have been studied [7-13]; however, various teams report opposing findings. It is even less 
clear how drying conditions such as those a lay herbalist would employ may affect 
bioactivity of Echinacea spp. roots. However, Perry et al. (2000) have reported that 
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alkamide levels dropped 80% when E. purpurea roots were stored at 24°C for 64 weeks [14], 
a method similar to that employed by lay herbalists. Data on the effects of longer-term 
storage (> 1 year) is lacking. Medicinal plants may be capable of retaining their medicinal 
properties long after harvest, as has been recently demonstrated with an 8 5-year-old 
specimen of black cohosh (Actaea racemosa L.) [15]. 
The effects of plant age on root bioactive constituent concentrations have also been 
investigated. However, the results of these studies are conflicting. The roots from older 
plants may contain increased, decreased, or similar levels of constituents compared to 
younger counterparts per the specific constituent [16, 17]. 
While numerous phytomedicinal studies of Echinacea spp. roots have been reported, 
only a handful of these reports state specifically that dried roots were employed. In vitro 
cytokine production from mouse splenocyte cultures stimulated with water and ethanol/water 
extracts of dried E. purpurea roots and leaves has been investigated. Various extracts 
increased production of IL-6, IL-10, MlP-la, and TNF-a, but not IL-2, IL-12, or IFN-y [4], 
In other studies, E. purpurea dried root powder has shown cyclooxygenase-inhibiting 
properties in both in vitro [18] and ex vivo [19] models. Granulocytes from mice fed 
Echinacea (several spp.) demonstrated higher levels of stimulation both during and 
immediately after the feeding period as compared to granulocytes from control mice [20]. 
Splenic lymphocytes from mice treated with E. purpurea dried root powder showed greater 
apoptosis resistance compared to non-treated controls, suggestively by downregulating Fas-
Ag expression and upregulating Bcl-2 expression at the cell surface [21]. In combination 
with roots of indigo (Baptisia tinctoria L. [Vent], Fabaceae) and shoots of cedar (Thuja 
occidentalis L., Cuppressaceae), extracts of dried E. pallida and E. purpurea roots lowered 
mortality, increased mean survival time, reduced lung consolidation, and reduced lung viral 
titer in mice infected with influenza Type A [22]. 
Despite these data, it is difficult to compare the results from different researchers 
because several important variables were not reported, including: (a) age of plant at time of 
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harvest; (b) length of drying time; (c) drying environment conditions; and (d) plant handling 
conditions (i.e., was the plant kept intact, portioned, chopped, etc.?). 
The aim of the present study was to investigate the effects of one and one half years 
of drying on the immunomodulatory properties of roots from seven Echinacea species using 
an older human adult model of influenza vaccination. Our hypothesis was that Echinacea 
spp. roots dried for one and one half years and then processed into alcohol tinctures would 
retain cytokine-modulating capabilities, although these effects would vary by species. To 
test this hypothesis, we isolated peripheral blood mononuclear cells from older humans (>64 
years of age) that had been vaccinated with the trivalent influenza vaccine 6-months prior to 
this study. Cells were incubated in vitro for 24 hours with Echinacea tinctures or control, 
along with influenza antigen. We tested supematants for synthesis of IL-2, IL-10, and IFN-y, 
cytokines known to be important in the immune response to upper respiratory infections such 
as influenza [23]. 
MATERIALS AND METHODS 
Plant collection, drying, and storage 
All plant material used in this study was harvested in December 2003 from the North 
Central Regional Plant Introduction Station in Ames, Iowa. Identification was authenticated 
by Dr. Mark Wildrlechner (Iowa State University). Every attempt was made to keep root 
bundles intact upon excavation; further, all aerial parts were left attached. The following 
species were collected and are given with their respective accession identifiers as well as the 
abbreviations by which they will be referred to in this publication: E. angustifolia var. 
strigosa (ANG; PI631302A), E. pallida (PAL; PI631275), E. paradoxa var. neglecta (PAR; 
PI631263), E. purpurea (PUR; unknown parentage), E. sanguinea (SAN; PI631257C), E. 
simulata (SIM; PI631304A), and E. tennesseensis (TEN; PI631250C). 
Whole plants were taken to the laboratory for temporary storage before being moved 
to a climate-controlled facility for sixteen months of storage. This room was held at 25.5-
26.5°C and 38% humidity during the study as determined by a separate temperature 
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hygrometer. Plants were hung upside down during this time. No special plant preparatory or 
drying procedures were used. 
Extract preparation 
Following sixteen months storage, plants were removed to the laboratory where 
ethanol tinctures consisting of 50% ethanol and 50% sterile water were prepared from roots. 
In all cases, plant cross-sections and/or shavings were produced using a surgical scalpel and 
combined with solvent as 1 part plant, 9 parts solvent. Preparations were steeped at room 
temperature for 20 minutes on a horizontal agitator before being filtered through sterilized 
tulle and stored at -20°C until use. 
HPLC 
Phytochemical analysis was performed to detect alkamides and caffeic acid 
derivatives in the Echinacea extracts with the use of high performance liquid 
chromatography (HPLC). Before analysis, into 160 gl of Echinacea extracts, 15 fil (1 mg ml" 
^) N-isobutylundeca-2-ene-8, lO-diynamide (C15H21O2) and 15 fxl (1 mg ml"1) 3,5-dimethoxy-
4-hydroxy-cinnamic acid (C11H12O5) were added as internal standards for quantification of 
lipophilic metabolites and hydrophilic metabolites, respectively. 
Fifteen microliters of each sample was injected into a Beckman Coulter HPLC with a 508 
autosampler, 126 pump control and 168 UV-photodiode array detector controlled by 32karat 
™ software (Version 5.0), and a YMC-Pack ODS-AM RP C18 (250 x 4.6 mm, 5 jum) 
analytical column (Waters, MA). The solvent system for lipophilic constituents was 
acetonitrile/HzO at a flow rate of 1.0 ml/min following a linear gradient of 40-80% 
acetonitrile over 45 min. The solvent system for hydrophilic constituents consisted of 
acetonitrile/H20 and 0.01% formic acid, at a flow rate of l.Oml/min following a linear 
gradient of 10-35% acetonitrile over 25 min. Online UV spectra were collected between 190-
400 nm. For compound identification, a mixture of Alkamide 8/9, cichoric acid, 
echinacoside, caftaric acid and cynarin were purchased from Phytolab, Germany; 
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chlorogenic acid was purchased from Sigma Aldrich, USA; alkamides 8, 10, 11, 12, 13, and 
14 and ketone 22 were synthesized by Dr. George Kraus, Department of Chemistry, Iowa 
State University [24, 25]. In the absence of standards, alkamides 1,2, 3, 4, 5, 7 and ketone 
24 were identified by HPLC fractionation coupled with GC-MS analysis. Phytochemicals 
were quantified based on the internal standard with the limit of HPLC detection at 
approximately 0.02 ng/ml. 
Human subjects and PBMC isolation 
All procedures involving human subjects were approved by the Institutional Review 
Board (ethics commission) at Iowa State University. Forty subjects were recruited. Subjects 
were >64 years of age by October 2004, when they received the trivalent influenza vaccine 
containing A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2), and 
B/Jiangsu/10/2003 (Aventis Pasteur, Swiftwater, PA). Six months post-vaccination (April 
2005), subjects returned to the laboratory for a blood draw to be used for testing the 
Echinacea extracts. Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll-
Paque plus (Amersham Pharmacopia Biotech, Piscataway, NJ) gradient centrifugation, 
counted manually using a hemacytometer, and adjusted to a concentration of 1.0 x 106 
cells/mL in AIM-V media (GIBCO/Invitrogen, Carlsbad, CA). 
Influenza-specific activation of PBMCs 
1.0 x 106 cells were plated per well in 24-well Costar plates. Each well received 
either 50 jj,L of one of the Echinacea preparations diluted 1:12.5 or a solvent vehicle control 
containing an equal volume of ethanol as the extract; the ethanol for the solvent vehicle 
control was diluted in AIM-V media. This extract concentration was used based on 
preliminary studies of cell ethanol tolerability (data not shown). Wells then received either 
the Al/New Caledonia virus or the A2/Wyoming virus identical to that contained in the 
vaccine at a concentration of 10 HA units/mL. Echinacea and virus were added 
simultaneously. Control wells received virus identical to Echinacea-txcatQd wells, but 
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received the solvent vehicle control instead of an Echinacea preparation. Control wells 
without virus do not typically contain detectable levels of cytokines, suggesting that cytokine 
production is antigen-specific. 
Cytokine assays 
Cells were incubated for 48 hours at 37°C, 5.0% carbon dioxide in humidified 
conditions for cytokine assay. Following incubation, the supematants were harvested and 
stored at -20°C until used in cytokine quantification assays. Cytokines (interleukin-2 [IL-2], 
IL-10, and interferon-y [IFN-y]) were quantified by ELISA (BD Biosciences Pharmingen, 
San Diego, CA). 
Endotoxin determination 
Measures were taken to minimized endotoxin contamination. All glassware was 
baked at 180°C for 24 hours prior to use. Sterile water was obtained from the manufacturer 
labeled for human medical use. Endotoxin levels were determined from both the sterile 
water (0 endotoxin units [EU]/mL) and from all final extracts using Bio-Whitaker QCL 1000 
kits (Cambridge, MA). Levels (in EU/mL) from the extract stocks were as follows: ANG 
8.925, PAL 8.553, PAR 9.817, PUR 8.999, SAN 9.222, SIM 8.255, TEN 9.743. 
To experimentally determine whether the endotoxin levels seen in the extracts 
influenced our immune outcomes, we isolated PBMC from four healthy, young adults 
according to the methods described above. Cells were cultured for 24 hours in AIM-V media 
with 50 p.L of stock concentrations of Eschereschia coli endotoxin at 10 EU/mL or 100 
EU/mL or sterile water (0 EU/mL). The 10 EU/mL stock represented an endotoxin level 
>12.5x higher than our Echinacea stock extract with the highest endotoxin level (PAR), and 
the 100 EU/mL stock represented an endotoxin level known to be immunostimulatory. 
Supematants were collected and cytokines (IL-2, IL-10, interleukin-l|3 [IL-1(3], and tumor 
necrosis factor-a [TNF-a]) quantified by ELISA (BD Biosciences Pharminge, San Diego, 
CA). 
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Statistical analyses 
A two-way ANOVA [species x virus type] was used to compare differences in 
cytokine production using SPSS (Chicago, IL) software. One-way ANOVA was used to 
determine the effects of different endotoxin doses on cytokine production. 
RESULTS 
Extracts prepared using methods similar to those of lay herbalists may harbor 
endotoxin from contaminating bacterial populations growing on the plant, and endotoxin is a 
known mitogen in vitro. To determine experimentally if endotoxin levels in our extracts 
may be influencing immune outcomes, we tested stock concentrations of E. coli endotoxin 
against human PBMC. Results are shown in Figure 3-1. Cytokine production from cells 
receiving the diluted stock of 10 EU/mL was not significantly different from control (0 
EU/mL) for IL-1(3 (p=0.995), IL-10 (p=0.973), and TNF-a (p=0.98); however, cells 
receiving the diluted stock of 100 EU/mL produced higher levels of cytokine as compared to 
control for IL-1(3 (p-0.068), IL-10 (p=0.044), and TNF-a (p=0.005). No differences were 
observed for IL-2, which is expected, as this is primarily a T-cell-produced cytokine with 
little responsiveness to endotoxin. 
The phytochemical analysis of our extracts for alkamides, ketones, and caffeic acid 
derivatives is presented in Table 3-1. ANG, PUR, and SAN had the highest concentrations 
of amides. PAL, PAR, and SIM had the highest concentrations of ketones. Results for 
caffeic acid derivatives differed by specific molecule. Overall, PUR had the highest total 
concentration of caffeic acid derivatives, and PAL had the greatest diversity of molecules. 
Results for interleukin-10 production are given in Figure 3-2. A significant main 
effect of plant species was observed (pO.OOl) as well as a plant species by virus interaction 
(p=0.038). Follow-up analyses were conducted separating H IN 1 and H3N2 results. For 
H1N1 alone, a significant effect of plant species remained (p=0.001). Four extracts 
stimulated significant increases in cell production of IL-10 compared to control condition 
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containing no Echinacea (Figure 3-2a): ANG (pO.OOl), PUR (pO.OOl), SIM (p=0.001), 
and TEN (p=0.002). PAL significantly decreased IL-10 production (Figure 3-2a; p=0.005). 
A similar pattern of results was found for the H3N2 virus. For H3N2 alone, a significant 
effect of plant species remained (pO.OOl). The same four extracts stimulated increases in 
IL-10 production (Figure 3-2b): ANG (pO.OOl), PUR (p=0.002), SIM (pO.OOl), and TEN 
(p=0.010). PAL again significantly decreased IL-10 production (pO.OOl). 
Results for interleukin-2 production are shown in Figure 3-3. A significant main 
effect of plant species was found (pO.OOl). All seven extracts induced statistically 
significant (all pO.OOl) reductions in IL-2 production compared to control condition 
containing no Echinacea. 
Results for interferon-y production are displayed in Figure 3-4. A significant main 
effect of plant species was observed (pO.OOl). No extracts significantly augmented IFN-y 
production. However, three extracts significantly diminished IFN-y synthesis: PAL 
(pO.OOl), PAR (pO.OOl), and SAN (p=0.003). 
DISCUSSION 
In this study, we employed an in vitro human older adult model of influenza 
vaccination to assess the bioactivity of Echinacea spp. roots dried for one-and-a-half years, 
specifically in regards to their ability to modulate patterns of cytokine expression in response 
to antigen challenge. This model had several virtues that made it readily amenable to the 
questions being addressed in this investigation. Echinacea extracts are typically taken for the 
prevention or treatment of upper respiratory infections such as influenza [26]. The model 
chosen here allowed us to test the efficacy of Echinacea extracts in an in vitro context of 
viral infection using human PBMC. The elderly are one segment of the population that 
typically consumes Echinacea preparations in an attempt to "boost" their immunity [27]. 
Influenza vaccine efficacy rates in geriatric populations are typically poorer than those of 
young adult controls, and influenza infection is a major cause of morbidity and mortality in 
this group [28]. Thus, results from this study may provide information on the potential 
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feasibility of using Echinacea preparations to improve influenza vaccine efficacy rates in 
older adults as well. In addition, a better understanding of how Echinacea may modulate 
cytokines in response to influenza virus challenge in vitro may be a first step in 
understanding the potential role of Echinacea during an influenza infection in vivo. 
The effects of endotoxin in our extracts were explored experimentally (Figure 3-1). 
Cells stimulated with endotoxin levels somewhat higher than levels in the extracts behaved 
no differently than controls that contained no endotoxin. These findings suggest that 
endotoxin levels in our Echinacea extracts did not influence the immune outcomes reported 
here. 
Results for our cytokine assays (Figures 3-2 through 3-4) are summarized in Table 3-
2. As is clear from these figures, even after one-and-a-half years of drying, Echinacea spp. 
roots maintained cytokine-modulating capabilities. A comparison of Table 3-2 with our 
phytochemical profile (Table 3-1) may shed light on the bioactive molecules responsible for 
our immune outcomes. 
We saw contrasting effects of different Echinacea spp. preparations on the production 
of interleukins. In general, Echinacea preparations tended to have no effect or increased 
production of IL-10 (Figure 3-2; Table 3-2). Table 3-1 does not suggest any single molecule 
or class of molecules that may be responsible for the IL-10 activities seen in Table 3-2. 
In contrast, all tinctures decreased production of IL-2 (Figure 3-3 ; Table 3-2). 
According to Table 3-1, amides and caffeic acid derivatives (but not ketones) were present in 
all species. Chlorogenic acid was the only molecule detectable in extracts from all seven 
species. It is possible that multiple alkamides or multiple caffeic acid derivatives may be 
responsible for this activity. 
One possible explanation for these results is that compounds in Echinacea somehow 
shift the Thl/Th2 balance. A prolonged Thl response (IL-2, IFNy) may result in 
inflammation and tissue damage, whereas an upregulation of the Th2 cytokine, IL-10, may 
have anti-inflammatory effects. This explanation may also support those studies finding a 
beneficial effect of Echinacea during viral infection. It is possible that following peak viral 
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load, preparations of Echinacea may promote a downregulation of the immune response by 
reducing inflammation via IL-10. 
However, the effects of Echinacea tinctures on IFN-y production were more 
ambiguous and do not completely fit a model of decreased Thl/Th2 cytokine ratio. Extracts 
seemed to variously increase or decrease production of this cytokine (Figure 3-4; Table 3-2). 
A statistically significant change was observed for PAL, PAR, and SAN, and was negative in 
all cases (see also discussion below). No single molecule or group of molecules from Table 
3-1 was unique to these three species, making it unclear which constituent(s) are responsible 
for these activities. Our results suggest that Echinacea preparations made in the manner 
employed here may not have a large effect on the production of IFN-y. It is possible that 
IFN-y may be more responsive to Echinacea during an actual infection rather than at 6 
months post-immunization when IFN-y levels in response to antigen have declined. 
Seven species of Echinacea were employed under the same experimental conditions, 
allowing us to make comparisons across taxa. The most consistent responses were seen from 
cells stimulated with PAL: in all cases, PAL induced decreases in cytokine production (Table 
3-2). Two other species, PAR and SAN, also decreased production of IL-2 and IFN-y, but 
not IL-10. ANG, PUR, SIM, and TEN augmented production of IL-10 and diminished 
production of IL-2; no effects were seen with IFN-y. These results imply that not all 
Echinacea species influence cytokine expression in similar fashions, supporting previous 
results from our lab [5] as well as others [29r31], More specifically, species such as PAL, 
PAR, and SAN tend to show repressive effects regardless of the cytokine being assayed, 
whereas species like ANG, PUR, SIM, and perhaps TEN stimulate cytokine-specific 
responses. Intriguingly, the three species employed for commercial preparations are ANG, 
PAL, and PUR, alone or in various combinations. Our results may indicate that the three 
species do not have similar effects, and may warrant a re-assessment of which species are 
included in commercial preparations and in what particular combinations. 
In conclusion, the results from this study suggest that Echinacea spp. roots dried for 
one-and-one-half years maintain cytokine-modulating capabilities. Additionally, they 
65 
suggest that different Echinacea spp. may act on cytokine expression in different fashions. 
Whether or not Echinacea extracts may have utility as influenza vaccine boosters and/or a 
beneficial role during actual influenza virus infection cannot be spoken to directly by this 
study; however, our in vitro findings do suggest the plausibility of such an application. 
Clinical in vivo studies using orally ingested Echinacea extracts in older adults receiving the 
influenza vaccine are needed to address these possibilities. Finally, more studies need to 
examine relationships between extract phytochemical composition and immunomodulatory 
activities to identify possible bioactive molecules and their associated effects. 
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Table 3-1. Phytochemical profile of extracts used in this paper as determined by HPLC. 
ANG" PAL PAR PUR SAN SIM TEN 
amide 1 0b 0 0 0.0456 0.0718 0 0 
amide 2 0.0059 0.0008 0 0.0159 0.0175 0 0 
amide 3 0.0059 0.0087 0 0.0310 0.2011 0 0 
amide 4 0.0059 0 0 0 0.0213 0 0 
amide 5 0.0124 0 0 0.0156 0 0 0 
amide 7 0 0 0 0.0092 0.0559 0 0 
amide 8 0.2798 0 0 0.2912 1.3138 0 0 
amide 9 0.0343 0 0 0.0396 0.3387 0 0 
amide 10 0.0368 0 0 0.0102 0.0378 0 0 
amide 11 0.0486 0 0 0.0106 0.0286 0 0 
amide 12 0.0371 0 0 0 0.2782 0 0.0024 
amide 13 0.0449 0 0 0 0.1444 0 0.0098 
amide 14 0.0141 0 0 0 0.4444 0 0.0085 
ketone 22 0 0.0540 0.0029 0 0 0.0148 0 
ketone 24 0 0.1668 0.0301 0 0 0.0093 0 
caftaric acid 0 0.0535 0 0.1568 0.0113 0.0359 0 
chlorogenic acid 0.0137 0.0079 0.0266 0.0157 0.0509 0.0069 0.0088 
cichoric acid 0 0.0141 0 1.0147 0 0 0 
cynarin 0.0223 0 0 0 0 0 0.0094 
echinacoside 0.0310 0.0885 0.1472 0 0 0.0476 0.0436 
a Species abbreviations are given in Methods. 
b Values are given in ug/mL. 
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Table 3-2. Summary of significant effects of Echinacea tinctures on cytokines produced by 
influenza-stimulated PBMC during in vitro culture. 
IL-2 IL-10 IFN-Y 
ANG* T ! 
PAL 1 1 1 
PAR 1 1 
PUR | Î 
SAM 1 1 
SIM | Î 
TEN | î 
a Species abbreviations are given in Methods. 
b Arrows indicate the direction of the immunomodulation in comparison to control values (t 
cytokine production; I = suppression of cytokine production; blanks indicate no change). 
= enhancement of 
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Figure 3-1. Cytokine production by PBMC stimulated with various levels of endotoxin: (a) 
IL-1(3, (b) TNF-a, (c) IL-10, (d) 1L-2. Bars represent standard errors. 
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Figure 3-2. IL-10 production by Echinacea tinctures under HIN1 (a), and H3N2 (b) 
stimulation. Bars represent standard errors. Note the direction of significance. Species 
abbrev ia t ions :  ANG (E .  angus t i fo l ia ) ,  PAL (E .  pa l l ida) ,  PAR (E .  paradoxa) ,  PUR (E .  
purpurea), SAN (E. sanguined), SIM (E. simulata), and TEN (E. tennesseensis). 
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Figure 3-3. IL-2 production by Echinacea tinctures under HIN1 (a), and H3N2 (b) 
stimulation. Bars represent standard errors. Species abbreviations: ANG (E. angustifolia), 
PAL (E .  pa l l ida) ,  PAR (E .  paradoxa) ,  PUR (E .  purpurea) ,  SAN (E .  sanguinea) ,  SIM {E .  
simulata), and TEN (E. tennesseensis). 
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Figure 3-4. IFN-y production by Echinacea tinctures under HIN1 (a), and H3N2 (b) 
stimulation. Bars represent standard errors. Species abbreviations: ANG (E. angustifolia), 
PAL (E .  pa l l ida ) ,  PAR (E .  paradoxa) ,  PUR (E .  purpurea) ,  SAN (E .  sanguined) ,  SIM (E .  
simulata), and TEN (E. tennesseensis). 
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CHAPTER 4. IMMUNOMODULATORY PROPERTIES OF ECHINACEA SPP. 
ROOT TINCTURES STORED AT -20°C FOR 2 YEARS 
A paper submitted to Journal of Pharmacy and Pharmacology1 
Dustin A. McCann,2 Filippo Macaluso,3 Marian L. Kohut,2,4 David S. Senchina4 
ABSTRACT 
Echinacea spp. phytomedicines are popular for treating upper respiratory infections. 
The purpose of this investigation was to examine the immunomodul atory properties of 
Echinacea tinctures from seven species stored at -20°C for two years. Two experimental 
techniques were employed using human peripheral blood mononuclear cells (PBMC). In the 
first set of experiments, PBMC were stimulated with tinctures alone and assayed for 
proliferation and production of interleukin-10 (IL-10), IL-12, and tumor necrosis factor-a 
(TNF-a). In the second set of experiments, subjects were immunized with influenza vaccine. 
The effect of Echinacea tinctures on PBMC production of influenza-specific cytokines (IL-2, 
IL-10, and interferon-y (IFN-y) were compared pre- and post-vaccination. In the first 
experiments: (a) tinctures from E. angustifolia, E. pallida, E. paradoxa, and E. tennesseensis 
stimulated proliferation and tended to increase IL-10; (b) E. sanguinea and E. simulata 
stimulated only proliferation; (c) E. purpurea stimulated only IL-10; and (d) none of the 
extracts influenced IL-12 or TNF-a. In the second experiments: (a) tinctures from E. pallida, 
E. paradoxa, E. sanguinea, and E. simulata diminished influenza-specific IL-2 and (b) none 
of the extracts influenced influenza-specific IL-10 or IFN-y. Two years storage at -20°C 
alters the immunomodulatory properties of Echinacea tinctures. For in vitro models using 
1 Submitted February 7, 2006 
2 Department of Health and Human Performance, Iowa State University 
3 Departimento di Medicina Sperimentale, Université di Palermo 
4 Immunobiology Program, Iowa State University 
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Echinacea, immune response may vary based on stimulus (.Echinacea alone vs. Echinacea + 
recall stimulation with virus). 
INTRODUCTION 
Complementary and alternative medicine use has greatly increased over the last two 
decades both in the United States and worldwide [1,2]. Currently, one of the more popular 
herbal remedies (phytomedicines) are supplements made from plants of the genus Echinacea 
[3], Known in vernacular as the purple coneflowers, this group of plants has been used to 
treat upper respiratory infections caused by rhino virus es or other cold viruses, or influenza 
viruses [3,4]. Other medicinal benefits have also been attributed to Echinacea, including 
anti-inflammatory [5, 6] and wound-healing [7] properties. 
The scientific literature regarding Echinacea's, efficacy in the context of upper 
respiratory infection is conflicting. Some studies have supported the use of Echinacea for 
colds and influenza [8, 9], In contrast, other investigations have refuted its efficacy [10, 11], 
Supplements prepared from Echinacea are generally considered safe, although a small 
number of adverse reactions have been reported [12]. 
Discrepancies among scientific reports may be attributable to many factors. Studies 
differ in the plant species used. Three species (Echinacea angustifolia, E. pallida, and E. 
purpurea) are used most widely [3]; however, it has been demonstrated that several other 
species in the genus also harbor medicinal activities [13, 14]. Studies also differ in the type 
of extract made and, within a given extract type, the precise mode of extraction. Some 
studies employ commercial preparations, whereas others generate their own extracts in the 
laboratory. Aside from the extracts themselves, differences in subject demographics (for 
example, age) may yield different results. Similarly, variations in experimental protocols 
may produce discrepant conclusions. 
While variables such as species used, type of extract, method of extraction, and 
subject demographics are frequently detailed in scientific reports, other unreported factors 
may also explain inconsistencies between studies. One such factor may be extract storage 
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conditions. For example, rarely do scientific reports state at what temperature or for how 
long their Echinacea extracts are stored before or during use. In a previous publication [13], 
we prepared Echinacea root tinctures and infusions using methods similar to those employed 
by lay herbalists and demonstrated that these extracts, when stored for four days at 4°C, 
changed in their immunomodulatory properties. 
In the present investigation, we tested aliquots from the same stock tinctures as in 
[13] that were stored at -20°C for two years for their abilities to modulate peripheral blood 
mononuclear cell (PBMC) proliferation and cytokine production. To our knowledge, no 
study has yet documented the effects of such storage on changes in Echinacea extract 
immunomodulatory activity, yet research laboratories typically freeze and reuse extracts over 
months or years. We expected that these extracts would show diminished 
immunomodulatory properties after storage compared to when they were tested fresh. 
However, we also expected that these properties might be changed when an antigen 
(influenza virus) was co-cultured with the cells of immunized donors. Few studies have 
examined Echinacea extracts in the context of antigen under controlled conditions. Extracts 
from seven Echinacea species were tested in two different in vitro models using PBMC from 
young adults. The first set of experiments used the tinctures themselves as the sole cell 
stimulus ("Echinacea alone model"). The second set of experiments compared the effects of 
Echinacea tinctures when used in conjunction with influenza virus (antigen) in vaccinated 
individuals ("Echinacea + virus model"). We chose to use two different experimental 
designs as some researchers have demonstrated in vitro immune outcomes may yield 
contrasting results contingent upon mitogen/antigen differences [15]. 
Immune parameters were selected due to their potential importance in the immune 
response to viral infection. The proliferation of lymphocytes in response to pathogen is an 
important component of the adaptive immune response, as expansions of lymphocytes such 
as T-cells is essential to combat infection. TNF-a is a cytokine that promotes an 
inflammatory response, which in the context of viral infection may be deleterious to the 
pathogen. However, excessive and/or prolonged levels of TNF-a may contribute to certain 
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disease states such as the pathology of influenza infection [16], inflammatory bowel disease 
[17], metabolic syndrome (including diabetes) [18], rheumatoid arthritis [19], and tissue or 
DNA damage [20]. In contrast to TNF-a, IL-10 is associated with anti-inflammatory 
activities. During viral infection, upregulation of IL-10 may lead to faster quelling of the 
inflammatory response, in turn leading to more rapid symptom resolution [21]. Indeed, the 
free oxygen radical-scavenging properties of Echinacea compounds [9] lends credence to 
this hypothesis. IL-12 has the ability to stimulate CD8+ T cell (cytotoxic T cell) responses; 
as CD8+ T cells can directly attack virally infected cells, augmentation of IL-12 may lead to 
enhanced viral clearance. Interleukin-2 is relevant in the context of viral infection as it 
enhances T-helper cell function and is thus a potential key player in the adaptive immune 
response. Finally, unique among the cytokines in this paper, IFN-y has direct antiviral 
activity and is also important in activating the cytotoxic lymphocyte response. 
MATERIALS AND METHODS 
Plant material and extraction procedure 
Three-year-old plant specimens grown from seed in outdoor fields were obtained 
from the USDA North Central Regional Plant Introduction Station (Ames, Iowa) in October 
2003. Seven species were harvested: Echinacea angustifolia var. angustifolia Ames 24994 
(ANG); E. pallida PI 631256 (PAL); E. paradoxa var. paradoxa PI 633664 (PAR); E. 
purpurea (unknown parentage; PUR); E. sanguinea Ames 23879 (SAN); E. simulata PI 
631251 (SIM); and E. tennesseensis PI 631250 (TEN). Voucher specimens for each plant 
used have been filed in the Ada Hayden Herbarium, Iowa State University (Ames, Iowa; ISC 
435974-435980). Roots were processed into extracts within 2.5 h following harvest using the 
methods in [13] and stored at -20°C for twenty-four months prior to this investigation. 
Extracts were diluted 1:12.5 in AIM-V media (GIBCO/Invitrogen, Carlsbad, CA) 
immediately prior to use. 
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Subject recruitment and immunization protocol 
Human subject protocols were filed and approved by the Institutional Review Board 
for Human Subjects. Twenty subjects participated in the first experiments not involving 
immunization and 21 subjects participated in the second experiments using influenza antigen 
as the immune stimulus. Twelve subjects participated in both studies. 
In Fall 2005, 21 subjects between the ages of 19-36 were immunized with the 
2005/2006 trivalent influenza Fluzone vaccine (A/New Caledonia/20/99 H1N1 [Al]; A/New 
York/55/04 H3N2 [A2]; B/Jiangsu/10/03; Aventis Pasteur, Swiftwater, PA) within 8 h 
following a pre-immunization blood draw. A second blood draw was performed at 4 weeks 
post immunization. One subject withdrew from the study and one subject had insufficient 
PBMC counts, resulting in a final pool of 19 subjects. 
PBMC isolation 
PBMCs were isolated using Ficoll-Paque plus (Amersham Pharmacopia Biotech, 
Piscataway, NJ) gradient centrifugation. Cell counts were performed with a hemacytometer 
using Trypan Blue to assess viability; all cell suspensions were adjusted to 2.0 x 106 cells/mL 
in AIM-V media. 
Cell culture for cell proliferation 
In the Echinacea alone model, one hundred |j.L of AIM-V media containing 2.0 x 106 
cells were plated per well in 96-well flat-bottom Costar plates. Cells were stimulated with 5 
p.L of Echinacea preparations diluted as above or AIM-V media (control; CON). All trials 
were conducted in triplicate. Cells were incubated for 5 d at 37°C, 5.0% carbon dioxide in a 
humidified atmosphere and proliferation assessed via CellTiter (Promega, Madison, WI) and 
read in a Bio-Rad plate reader (Hercules, CA). Our sample size for proliferation was n=15. 
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Cell culture for cytokine production 
In the Echinacea alone model, one mL of AIM-V media containing cells (2.0 x 106 
cells) was plated per well in 24-well Costar tissue culture plates. Fifty pL of one of the 
Echinacea preparations diluted 1:12.5 was added per treatment well; the control well 
received 50 pJL of AIM-V media (CON). This extract concentration was determined from 
preliminary studies of human PBMC ethanol tolerability (data not shown). Cell cultures for 
IL-10, TNF-a, and IL-12 were incubated for 24 h at 37°C, 5.0% carbon dioxide in a 
humidified atmosphere. Supernatants were harvested and stored at -20°C until used in 
cytokine quantification assays for IL-10, TNF-a, and IL-12 via ELISA (BD Biosciences 
Pharmingen, San Diego, CA). Due to low PBMC counts, our sample size for IL-10 and 
TNF-a was n-l4 and for IL-12 n = 17. 
In the Echinacea + virus model, one mL of AIM-V media containing cells (2.0 x 106 
cells) was plated per well in 24-well Costar tissue culture plates. Fifty j_tL of one of the 
Echinacea preparations diluted 1:12.5 was added per treatment well. All treatment wells 
received 50 pL of a 10 HAU/ml solution containing the same Type A H1N1 virus (A/New 
Caledonia/20/99) as in the vaccine. Two control wells were designated, one received 100 pL 
of AIM-V media (CON), whereas the other received 50 p.L of AIM-V media and 50 
microliters of virus (VIR). Cell cultures for IL-2 and IFN-y were incubated for 48 h at 37°C, 
5.0% carbon dioxide in a humidified atmosphere. Cell cultures for IL-10 were incubated at 
both 24 h and 48 h under the same conditions. Supernatants were harvested and stored at -
20°C until used in cytokine quantification assays for IL-2, IL-10, and IFN-y via ELISA (BD 
Biosciences Pharmingen, San Diego, CA). Due to experimental complications during testing 
of the extracts, our sample size for IFN-y was reduced to n=8; for all other cytokines, the full 
n-19 was used. Control experiments indicated that for all assays, wells receiving no virus 
produced less cytokine than wells receiving virus alone (all p < 0.01). 
Statistical analyses for the Echinacea alone model 
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A one-way ANOVA was used to compare the effects of the different species of 
Echinacea on cytokine production and cell proliferation. Post hoc tests were performed 
when a significant effect of treatment was found. 
Statistical analyses for the Echinacea + virus model 
A general linear model of repeated measures was used to test for main effects of time, 
treatment, and treatment x time interactions (SPSS, Chicago, IL). When significant effects 
were discovered, follow-up posthoc tests (LSD) were performed. 
Endotoxin determination 
Glassware used in the extract preparation was baked at 180°C for 16 h prior to use to 
minimize endotoxin contamination. Sterile water was obtained from Hospira, Inc., Lake 
Forest, IL and used for all tinctures. Endotoxin levels were determined from both sterile 
water (0 EU/mL) and all stock tinctures using Bio-Whitaker QCL 1000 kits (Cambridge, 
MA). 
RESULTS 
Endotoxin levels 
Endotoxin levels were determined from all extracts previously and are as follows (in 
EU/mL): ANG (0.088), PAL (0.031), PAR (0.116), PUR (0.395), SAN (0.03), SIM (0), and 
TEN (0.108). All extracts were diluted following a procedure outlined in Methods, with final 
endotoxin concentrations in the wells (expressed as EU/mL) being: ANG (0.0003), PAL 
(0.0001), PAR (0.0004), PUR (0.0014), SAN (0.0001), SIM (0), TEN (0.0004). Elsewhere, 
we have shown experimentally [22] that these low levels of endotoxin do not influence our 
immune outcomes. These results suggest that the effects observed in our assays are due to 
Echinacea extracts themselves rather than possible contaminating bacterial endotoxin. 
PBMC proliferation at 5 d in the Echinacea alone model 
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Results for PBMC proliferation following 5 d incubation are shown in Fig 1. A main 
effect of treatment was observed (p = 0.003). Wells treated with ANG (p < 0.001), PAL (p < 
0.001), PAR (p < 0.001), SAN (p = 0.036), SIM (p < 0.001), and TEN (p < 0.001) showed a 
significant increase in PBMC proliferation as compared to control (CON). 
Cytokine production at 24 h in the Echinacea alone model 
Table 4-1 displays our results for TNF-a and IL-12. No main effect of treatment was 
observed (p = 0.164 and p = 0.142, respectively). IL-10 production following 24 h 
incubation is displayed in Fig 2. Results indicate a trend towards a significant effect of 
treatment (p = 0.085) such that Echinacea treatment may slightly enhance IL-10 production 
to a limited extent. 
Interleukin-2 production in the Echinacea + virus model 
Results for interleukin-2 production following 48 h culture are presented in Figure 4-
3. There was a main effect of treatment (p = 0.029), such that Echinacea tended to cause a 
decrease in IL-2 production. Wells treated with PAR (p = 0.012) and SAN (p = 0.044) 
demonstrated significantly decreased IL-2 production compared to wells receiving virus 
alone, whereas wells treated with PAL (p = 0.084) and SIM (p = 0.08) showed a trend in this 
direction. No time or treatment x time interaction was found. 
Interleukin-10 production in the Echinacea + virus model 
Production of interleukin-10 following 24 h and 48 h culture is displayed in Table 4-
2. There was a main effect of time (p < 0.001) such that subjects produced more IL-10 at the 
post-vaccination time point compared to pre-vaccination time point in both the 24 and 48 h 
cultures. There were no main effects of treatment or any treatment x time interactions for 
either incubation time. 
Interferon- y in the Echinacea + virus model 
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Results for IFN- y production following 24 h culture are presented in Table 4-2. 
Subjects produced more IFN- y post-vaccination than pre-vaccination indicating a main 
effect of time (p = 0.005). There was no main effect of treatment or treatment x time 
interaction. 
DISCUSSION 
In this paper, both antigen-independent (.Echinacea alone) and antigen-dependent 
(.Echinacea + virus) models were deployed to examine the effects of Echinacea tinctures on 
various immune parameters potentially important in the course of viral infection. Results 
have been summarized in Table 4-3. We selected these particular immune parameters as they 
are potentially important factors in the host response to upper respiratory infection, as was 
elaborated in the introduction, and because these parameters have been studied from fresh 
extracts, thus allowing for a comparison of storage effects. 
Echinacea alone model 
When our laboratory examined the proliferation-enhancing capabilities of these same 
extracts freshly-prepared, none of the tinctures modulated proliferation [13]. We therefore 
expected that none of the extracts would enhance proliferation in this current study (i.e., after 
2 years storage at -20°C). Contrary to our initial expectations, all Echinacea tinctures except 
those from E. purpurea enhanced PBMC proliferation in the Echinacea alone model (Figure 
4-1). The tincture from E. purpurea produced a similar mean level of proliferation as E. 
angustifolia and E. sanguinea, but the standard deviation was larger, leading to a lack of 
significance. Thus, these results may indicate that long-term storage of Echinacea tinctures 
at -20°C increases their capacity to augment PBMC proliferation. 
Data on the effects of Echinacea on PBMC proliferation or proliferation of specific 
lymphocyte subpopulations is conflicting. Some studies have demonstrated that the 
proliferation of T cells, a component of the adaptive immune system, appears to be 
minimally impacted by Echinacea supplementation [23, 24]. Another study showed no 
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effect of Echinacea supplementation on porcine PBMC proliferation [25]. Alternatively, it is 
possible that Echinacea may impact on PBMC proliferation indirectly; for example, 
Echinacea may stimulate macrophages which in turn drive proliferation of lymphocytes such 
as T-cells [26], or that the effects of Echinacea on proliferation are contingent on the 
maturity state of the cell [27]. In contrast, results from this study and previous data from our 
laboratory [28] and others [29, 30] suggest Echinacea may have some effect on PBMC 
proliferation, potentially due to components such as polysaccharides. Considered together, 
these results suggest that the polysaccharide component of Echinacea may harbor PBMC 
proliferation-stimulating properties; this component may or may not be present in Echinacea 
supplements depending on the mode of extraction. No studies have documented the effects of 
extract storage on Echinacea polysaccharides. 
None of the Echinacea tinctures modulated TNF-a production in the nonviral model 
(Table 4-1). When these same extracts were tested fresh [13], both E. angustifolia and E. 
purpurea demonstrated an ability to increase TNF-a synthesis. These results suggest that the 
ability to enhance TNF-a production may be lost by Echinacea tinctures stored under these 
conditions. 
The majority of studies examining the effects of Echinacea on TNF-a production 
have shown a stimulatory effect in both human and rodent models [13, 29, 31-33], One 
insightful study showed that Echinacea may act on the cannabinoid receptor 2 (CB2), thus 
influencing TNF-a gene expression [33]. Therefore, transiently elevated TNF-a levels (that 
may be achieved by short-term Echinacea supplementation) may be beneficial in combating 
viral infections, but may be deleterious if a chronic inflammatory disease is present. 
Echinacea alkylamides [33, 34] and polysaccharides [29, 35] are known to influence TNF-a 
production. The effects of longer-term extract storage on a class of compounds related to 
alkylamides (the alkamides), has been studied. One team stored a hydroalcoholic preparation 
of E. purpurea root at -25°C for 7 months and found no significant changes in alkamide 
content [36]. Perhaps 24 months of storage is sufficient to cause a reduction in alkylamides, 
or the effects observed here with TNF-a may be unrelated to alkylamide content. 
85 
Echinacea tinctures showed a trend towards increasing IL-10 production in this 
investigation (Figure 4-2). In our prior investigation using the same tinctures fresh [13], only 
E. angustifolia harbored this ability. This comparison suggests that the ability of Echinacea 
tinctures to modulate IL-10 production may be enhanced during long-term storage at -20°C. 
However, the degree of augmentation observed here is so low that it may not be of 
physiological relevance. 
Several publications have reported a stimulatory effect of Echinacea spp. extracts on 
IL-10 production [13, 22, 28, 31, 32]; however, our lab has shown that E. pallida extracts 
may sometimes have IL-10-suppressing tendencies [22]. Taken together, the accumulated 
data imply that most Echinacea extracts harbor the ability to augment IL-10 production, 
which may lead to a faster resolution of viral infection symptoms. It is presently unknown 
which Echinacea constituents may be responsible for modulating IL-10 production. 
None of the extracts influenced IL-12 production (Table 4-1). When these same 
extracts were tested fresh [13], the E. angustifolia tincture increased IL-12 synthesis. These 
results suggest that long-term storage at -20°C diminishes what little IL-12 modulating 
capacities Echinacea tinctures may have. 
Few reports have documented a stimulatory effect of Echinacea spp. preparations on 
IL-12 [13, 32] and one study showed it had little effect [37]. The biochemical fraction 
responsible for this activity is unknown. The limited data thus suggest that Echinacea holds 
only modest abilities to influence IL-12 production. 
Effects of two years storage at -20 °C 
The results presented here (Figs. 1-2, Table 4-1) allow for a comparison between the 
same extracts tested under the same assays fresh [13] and after two years storage at -20°C. 
Cold storage appears to augment the ability of Echinacea tinctures to stimulate PBMC 
proliferation and possibly IL-10 synthesis and diminish their ability to stimulate TNF-a 
synthesis, while having no effect on IL-12. Taken together, our findings indicate that 2 years 
storage at -20°C does indeed alter the immunomodulatory properties of Echinacea tinctures. 
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Also possible, the differences observed between this study and the previous investigation 
may be due to size sample between the two studies. 
Our findings may have important ramifications for scientists examining Echinacea 
extracts. Temperature of storage and time of storage both appear to be important factors in 
determining how Echinacea extracts may behave in in vitro experiments. This observation 
complicates a comparison of studies from different investigators, as storage conditions 
frequently go unreported. Further, if temperature and time factors are indeed important, 
differences in these variables may explain the discrepant results submitted by different 
laboratories. As noted earlier, only one study [36] has documented the effects of time and 
temperature of extract storage on biochemical markers, finding little changes in alkamide 
content but significant declines in cichoric acid, a phenolic component. 
Echinacea + virus model 
We found that interleukin-2 levels did not differ significantly between pre- and post-
vaccination PBMC cultures, contrary to our expectations as influenza immunization has 
typically been associated with increased antigen-induced IL-2. It is likely that IL-2 
production peaked at an earlier time point than at 48 h, when supernatants were collected in 
this experiment. Previously, we explored Echinacea extracts in an older adult model of 
influenza vaccination [22] and found that IL-2 production peaked at 48 h, but in younger 
adults with more robust immune systems this climax may come at an earlier time point (such 
as 24 h); hence, by 48 h, secreted IL-2 may have already been taken up by target cells, such 
that the overall amount detected in supernatants appears to be lower. 
However, four species (E. pallida, E. paradoxa, E. sanguinea, and E. simulata) did 
notably decrease IL-2 production as compared to wells receiving virus without Echinacea 
extract (Figure 4-3). These results using Echinacea are consistent with findings previously 
from our lab. In another investigation using Echinacea extracts derived from dried roots of 
the same species and an older adult model of influenza vaccination, we found that extracts 
from all seven species significantly reduced IL-2 production at 6-months post-immunization 
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[22]. Decreased IL-2 production overall is a known consequence of ageing 
(immunosenescence, reviewed in [38]) and may explain why some species (E. angustifolia, 
E. purpurea, and E. tennessensis) depressed IL-2 production in the older adult study but not 
in this report with young adults. 
Echinacea products have been shown to increase [39, 40], decrease [22], and have no 
effect [28, 29,41] on IL-2 levels in a variety of human and rodent models; however, our 
laboratory is the only one that has used antigen activation. Thus, the effect of Echinacea on 
IL-2 is currently ambiguous, possibly attributable to differences in experimental methods 
between studies. 
Interleukin-10 production was assayed at both 24 and 48 h time points in culture with 
virus. Under both time designations, post-vaccination levels of IL-10 were higher than pre-
vaccination levels. This change from pre to post may indicate that subjects had an enhanced 
response to the virus as a result of vaccination. In this experiment, Echinacea tinctures 
overall had no discernible influence on IL-10 production (Table 4-2). In a separate study 
using an older adult model of influenza vaccination and Echinacea tinctures [22], we found 
that E. angustifolia, E. purpurea, E. simulata, and E. tennesseensis tinctures enhanced IL-10 
production, whereas E. pallida tinctures diminished IL-10 production. These discrepancies 
may be explained by age differences in the subjects or due to differences in the extracts 
themselves, as the extracts used in the older adult model were produced from dried roots and 
stored for less than 4 days at -20°C before being used. 
Interestingly, when virus was not employed during the 24 h culture (Figure 4-2), E. 
angustifolia, E. pallida, E. paradoxa, E. purpurea, and E. tennesseensis all slightly increased 
IL-10 synthesis, but again these increases are of dubious physiological relevance. Therefore, 
a comparison of Figure 4-2 and Table 4-2 suggests that Echinacea's effects (with respect to 
IL-10) are not contingent on the presence of virus. In the context of viral infection, our 
results seem to suggest that the effects of Echinacea on IL-10 may vary based on mode of 
activation, cell type, and possibly other factors. 
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Individuals produced higher levels of IFN-y post-vaccination compared to pre-
vaccination, suggesting that immunization produced a greater number of antigen-specific 
cells that exhibited a recall response to the virus in vitro post-immunization. However, the 
presence of Echinacea did not alter this response (Table 4-2). When PBMC from vaccinated 
older adults were used [22], tinctures from E. pallida, E. paradoxa, and E. sanguinea all 
diminished IFN-y production. Again, the differences observed between the responses of 
young subjects from this study and older adult subjects in a previous study may be due to age 
differences or extract differences. 
Extracts from Echinacea have previously been shown to increase IFN-y synthesis [30, 
40,42, 43] in most models. However, some teams found no effect of Echinacea on IFN-y 
[29, 41] and our investigation in vaccinated older adults showed Echinacea decreasing IFN-y 
levels [22]. Melanin is one component from Echinacea that is frequently lost in common 
extraction methods that harbors this ability [44]. In a separate investigation, Echinacea 
stimulation increased gene expression of IFN-a, also antiviral [45]. One in vivo model 
showed oral supplementation with E. purpurea increased circulating IFN-y titers [37]. Taken 
together, these results suggest that Echinacea extracts may be able to augment interferon 
production, which may directly reduce viral load in the host during infection, though the 
enhancement is general rather than specific to antigen. 
Effects by species 
While we have focused on the effects of Echinacea extracts overall on the immune 
parameters studied here, it is important to clarify that these effects vary by the species 
selected. This phenomenon is highlighted in Table 4-3. Four species (.Echinacea pallida, E. 
paradoxa, E. sanguinea, and E. simulata) behaved similarly in all eight immune assays, 
increasing PBMC proliferation in the nonviral model and decreasing IL-2 production in the 
viral model. The similarities between E. pallida and E. sanguinea are not surprising. In a 
recent phenetic analysis of seven species of Echinacea based on their modulation of 25 
immune parameters, these two species were found to be most similar to each other [46]. 
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However, E. simulata formed a species-pair with E. angustifolia, and this species-pair was 
maximally dissimilar from the E. pallida+E. sanguinea species-pair. In this investigation, 
these four species do not appear to be very different from one another. As the phenetic 
analysis was based on a much larger pool of characteristics than given here, it could be that 
the eight parameters in this paper are too small of a sample to yield an accurate representation 
of the immunomodulatory relationships between the seven Echinacea species. 
Echinacea angustifolia and E. tennesseensis also behaved similarly, as they both 
increased PBMC proliferation and IL-10 production in the nonviral model and had no effect 
on IL-2 in the viral model; additionally, E. tennesseensis was able to augment IL-10 
production at 24 h in the viral model. By contrast, the only statistically significant activity 
seen from E. purpurea was an enhancement of IL-10 production in the nonviral model. 
However, results variability was greater for E. purpurea in some instances, and this may 
explain why E. purpurea appeared to be the least active. 
Concluding remarks 
We found that Echinacea tinctures had no effect on TNF-a (a pro-inflammatory 
cytokine produced by macrophages) in the nonviral model, but did alter response to several T 
cell-associated parameters (such as IL-2 and IL-10) in both the nonviral and viral models. 
Reductions in IL-2 (a Thl cytokine) may inhibit T cell proliferation, whereas increases in IL-
10 (a Th2 cytokine) may minimize an inflammatory response such as that produced in the 
presence of TNF-a. Thus, in the context of viral infection, the tinctures in this investigation 
might exert their effects by downregulating an immune response. This behavior may be 
physiologically beneficial, as it may expedite the healing process following infection. The 
data presented here support our hypothesis, founded on previous data [22] that, in the context 
of viral infection, Echinacea tinctures may induce a shift in the Thl/Th2 balance. If this is 
true, the benefit of consuming Echinacea preparations may not be to fight the viral infection 
per se, but more so to alleviate the symptoms wrought by the immune response to infection, 
as other investigators have also suggested [9, 47]. 
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Table 4-1. TNF-a and IL-12 results from the Echinacea alone model. 
Parameter 
Species8 TNF-a IL-12 
CON 14.08+ 1.95b 11.88 + 1.36 
ANG 16.33 ±2.17 12.27 ± 1.31 
PAL 14.5 ±1.87 11.71 ± 1.41 
PAR 14.92 ± 1.86 11.9 ± 1.38 
PUR 15.66 ± 1.79 12.16 ± 1.35 
SAN 22.18 + 5.89 10.98 ± 1.59 
SIM 13.4 ± 1.77 10.93 ± 1.54 
TEN 20.11 ±2.65 10.43 ± 1.4 
a CON represents control values. Species abbreviations are given in Methods. 
b Values represent means ± standard errors in pg/mL. 
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Table 4-2. IL-10 and IFN-y results from the Echinacea + virus model. 
Parameter 
Species3 IL-10 at 24 h IL-10 at 48 h IFN-Y 
CON 12.72 ±1.9^ 14.42 ±3.33 3.01 ± 1.05 
VIR 19.75 ±1.97 105.91 ± 17.65 934.21 ± 168.82 
ANG 27.68 + 3.48 123.58 ± 16.38 960.73 ± 166.01 
PAL 30.98 ±7.56 103.09 ± 15.11 693.92 ± 103.92 
PAR 41.58 ±22.75 135.49 ±57.47 650.31 ± 118.27 
PUR 23.17 ±2.65 108.89 ± 17.22 771.31 ± 170.93 
SAN 25.25 ±8.01 95.16 ± 13.69 693.18 ± 117.99 
SIM 22.91 ±4.24 80.46 ± 15.07 546.1 ±73.7 
TEN 55.04 ± 19.37 100.19 ±16.23 853.08 ± 123.93 
a CON represents control values. Species abbreviations are given in Methods. 
b Values represent means ± standard errors in pg/mL. 
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Table 4-3. Summary of cytokine production and proliferation from the Echinacea alone and 
the Echinacea + virus models. 
Model Immune Parameter ANGa PAL PAR PUR SAN SIM TEN 
Echinacea PBMC proliferation f t î N f f T~ 
alone 
TNF-a N N N N N N N 
IL-10 T T T T N N T 
IL-12 N N N N N N N 
Echinacea IL-2 N I ^ N X I N 
+ virus 
IL-10 at 24 h N N N N N N N 
IL-10 at 48 h N N N N N N N 
IFN-y N N N N N N N 
a Species abbreviations are given in Methods. 
b For species outcomes, the symbol "Î" indicates significant enhancement of cytokine production compared to 
the control, whereas the symbol "4" indicates significant decrease in cytokine production compared to the 
control (or a trend in this direction); "N" indicates "no change" compared to control. 
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Figure 4-1. PBMC proliferation in the Echinacea alone model. Species abbreviations are 
described in Methods. Asterisks indicate statistically significant (p < 0.05) increases in wells 
receiving Echinacea tincture compared to control (media alone) wells. 
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Figure 4-2. IL-10 production in the Echinacea alone model. Species abbreviations are 
described in Methods. Asterisks indicate statistically significant (p < 0.05) increases in 
receiving Echinacea tincture compared to control (media alone) wells. 
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Figure 4-3. IL-2 production in the Echinacea + virus model: (a) pre-immunization; (b) post-
immunization. Species abbreviations are described in Methods. Double asterisks (**) denote 
statistically significant (p < 0.05) decreases in wells receiving Echinacea tincture compared 
to control (media alone) wells. Double daggers ("ft) denote a statistical trend (0.1 < p < 0.05) 
towards a decrease in wells receiving Echinacea tincture compared to control. 
b T 
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CHAPTER 5. PHYTOMEDICINAL PROPERTIES OF ECHINACEA 
TENNESSEENSIS VARY BY PLANT ORGAN 
A paper submitted to Fitoterapia1 
David S. Senchina,2,3 Dustin A. McCann,3 Gina N. Flinn,4 Zili Zhai,5 Joan E. Cunnick,2,3 
Marian L. Kohut2'3 
ABSTRACT 
Background: Members of the genus Echinacea are used medicinally to treat upper 
respiratory infections such as colds and influenza. Little scientific data exists regarding the 
phytomedicinal properties of the majority of species. The aim of the present investigation 
was to characterize the phytomedicinal properties of the American federally endangered 
species Echinacea tennesseensis. Methods: Fifty-percent ethanol tinctures were prepared 
from roots, stems, leaves, and flowers and tested separately for their ability to stimulate 
production of IL-1 (3, IL-2, IL-10, and TNF-a as well as proliferation by young human adult 
peripheral blood mononuclear cells (PMBC) in vitro. Tincture aliquots were stored at three 
different temperatures (4°, -20°C, and -80°C) for 21 h before testing. At one-month post-
extraction, tinctures stored at -20°C were tested again for cytokine modulation. Results: 
Fresh root, leaf, and flower tinctures stimulated PBMC proliferation. Only fresh root 
tinctures stimulated IL-1(3, IL-10, and TNF-a production, whereas none of the tinctures 
modulated IL-2 production. Stem tinctures showed no activity. Storage temperature did not 
influence any outcomes. Root tinctures maintained their ability to modulate IL-1 p, IL-10, 
and TNF-a production after one month of storage at -20°C. Conclusions: These results 
suggest E. tennesseensis harbors phytomedicinal properties that vary by plant organ, with 
1 Submitted December 30, 2005 
2 Immunobiology Program, Iowa State University 
3 Department of Health and Human Performance, Iowa State University 
4 Department of Genetics, Iowa State University 
5 Department of Animal Science, Iowa State University 
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roots harboring the strongest activities. Root tincture immunomodulatory activity was 
maintained following one month of storage at -20°C. 
INTRODUCTION 
Alternative medical therapies, including herbal preparations such as those from 
Echinacea spp., are gaining use in the United States [1,2]. The genus Echinacea is used 
most frequently for preventing or treating upper respiratory infections such as colds and 
influenza [3,4], However, while some studies have supported its use in this capacity [5-8], 
others have suggested it may be ineffective [9-12]. Since Echinacea angustifolia, E. pallida, 
and E. purpurea are used commercially, these three species have received the overwhelming 
majority of scientific attention and much data exists regarding their genetics, phytochemistry, 
immunomodulatory activity, and efficacy in clinical settings [13]. By comparison, very little 
is known about the American federally endangered species E. tennesseensis. 
Most of the published work has focused on Echinacea tennesseensis' phytochemistry. 
Several classes of purported medicinal compounds have been identified from this genus, but 
current data suggest that no single molecule or class of molecules is responsible for 
Echinacea's activities [13]. Three diacetylenic isobutylamides (polyacetylenes) have been 
identified from E. tennesseensis seedlings. Further, in a cross-genus comparison, it was 
shown that E. tennesseensis harbors higher levels of one of these compounds (amide 5) as 
compared to other members of the genus [14]. In contrast, other bioactive molecules, such as 
phenolic compounds (including caffeic acid derivatives), were found to be lower in E. 
tennesseensis root extracts than in extracts from other sister species [15]. Levels of alkenes, 
amides, and caffeic acid derivatives from E. tennesseensis root extracts in comparison to 
sister species have been reported [16]. In particular, this species harbors higher levels of 
several monoene and tetraene amides (phytochemicals with demonstrated antiviral activity), 
but perhaps lower levels of caffeic acids and their derivatives, compared to other Echinacea 
species. 
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Previously, our lab reported that E. tennesseensis root extracts may harbor 
immunomodulatory properties [17]. We found that 50% ethanol/50% sterile water tinctures 
from this species had the capacity to enhance TNF-a production while suppressing IL-12 
production by human peripheral blood mononuclear cells (PBMCs) cultured in vitro. We 
also showed that these ethanol/water tinctures were more active than cold or hot water 
infusions made from the same plant stock. In a subsequent investigation, we further 
characterized the phytomedicinal properties of E. tennesseensis root tinctures using a human 
older adult model of influenza vaccination [18]. In the context of influenza virus-stimulated 
PBMCs from individuals vaccinated against influenza, we showed that E. tennesseensis root 
tinctures augmented IL-10 production, diminished IFN-y production, and had no effect on 
IL-2 production. 
The aim of the present work was to more fully characterize the immunomodulatory 
properties of E. tennesseensis. To achieve this aim, we prepared ethanol tinctures from roots, 
stems, leaves, and flowers separately and tested their abilities to modulate PBMC production 
of IL-1(3, IL-2, IL-10, and TNF-a, as well as PBMC proliferation. We also investigated 
whether storage temperature conditions influenced outcomes. 
MATERIALS AND METHODS 
Plant material 
A lone individual of Echinacea tennesseensis (PI631250) was harvested from a field 
population at the North Central Regional Plant Introduction Station in Ames, Iowa on June 
21,2005. The plant was processed into extracts less than 3 h after harvesting. 
Extract preparation and handling 
The plant was rinsed with Nanopure water. Roots, stems, leaves, and flowering tops 
were separately minced with a surgical scalpel and dissolved in 50% ethanol and 50% sterile 
water at a ratio of 1 part plant, 4 parts solvent to generate ethanol tinctures. Preparations 
steeped at room temperature for 1 h on a horizontal agitator before being filtered through 
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sterilized tulle. Tinctures were fractionated into three aliquots for storage at 4°C, -20°C, and 
-80°C. To mimic the freeze/thaw cycles that laboratory extracts typically experience as a 
result of repeated handling for separate experiments, all aliquots were removed and brought 
to room temperature every 7 h for 21 h (total 3 cycles). Following initial testing of the fresh 
extracts, the -20°C aliquots were saved and tested again 1 month later. We chose the aliquots 
stored at this temperature because this is the typical storage temperature used in many 
laboratories. Extracts will be referred to as "Day 1" or "Day 31" in this report. 
PBMC isolation 
All procedures involving human subjects were approved by the Institutional Review 
Board of Iowa State University. Sixteen subjects between the ages of 19-36 donated blood 
for the testing of the fresh extracts. Four of these same subjects donated blood for the testing 
of the one-month-old extracts. Peripheral blood mononuclear cells (PBMCs) were isolated 
using Ficoll-Paque plus (Amersham Pharmacopia Biotech, Piscataway, NJ) gradient 
centrifugation. Cell counts were performed with a hemacytometer using Trypan Blue to 
assess viability; all cell suspensions were adjusted to 1.0 x 106 cells/mL in AIM-V media 
(GIBCO/Invitrogen, Carlsbad, CA). 
Echinacea tennesseensis modulation of cytokine production 
One mililiter of AIM-V media containing cells (1.0 x 106 cells) was plated per well in 
24-well Costar tissue culture plates. Fifty microliters of one of the Echinacea preparations 
diluted 1:12.5 was added per treatment well; the control well received 50 microliters of AIM-
V media. This extract concentration was determined from preliminary studies of human 
PBMC ethanol tolerability (data not shown). Cell cultures were incubated for 24 h at 37°C, 
5.0% carbon dioxide in a humidified atmosphere. Supematants were harvested and stored at 
-20°C until used in cytokine quantification assays for IL-ip, IL-2, IL-10, and TNF-a via 
ELISA (BD Biosciences Pharmingen, San Diego, CA). Due to experimental complications 
during testing of the fresh extracts, our sample size for IL-2 was n=14 and for IL-10 n=8. 
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Echinacea tennesseensis modulation of PBMC proliferation 
One hundred microliters of AIM-V media containing 1.0 x 106 cells were plated per 
well in 96-well flat-bottom Costar plates. Cells were stimulated with 5 microliters of 
Echinacea preparations diluted as above or AIM-V media (control). All trials were 
conducted in triplicate. Cells were incubated for 5 d at 37°C, 5.0% carbon dioxide in a 
humidified atmosphere and proliferation assessed via CellTiter (Promega, Madison, WI) per 
manufacturer's instructions and read in a plate reader (Bio-Rad, Hercules, CA). 
Endotoxin determination 
All glassware used in the extract preparation was baked at 180°C for 16 h prior to use 
to minimize endotoxin contamination. Sterile water was obtained from Hospira, Inc., Lake 
Forest, IL and used for all tinctures. Endotoxin levels were determined from both sterile 
water (0 EU/mL) and all stock tinctures using Bio-Whitaker QCL 1000 kits (Cambridge, 
MA). 
Statistical analyses 
A two-way ANOVA (plant organ and storage temperature) was used to evaluate the 
effect of Echinacea tennesseensis on each cytokine or measure of proliferation with the 
appropriate post-hoc tests performed using LSD (SPSS, [Chicago,IL]). 
RESULTS 
Endotoxin effects 
Endotoxin levels from all stock extracts were determined and are as follows (in 
EU/mL): root (23.611), stem (1.252), leaf (1.464), flower (9.708). As described in Methods, 
the extracts were diluted before being added to the wells. Thus, final endotoxin 
concentrations (EU/mL) in the cell culture wells were: root (0.086), stem (0.005), leaf 
(0.005), flower (0.035). We have demonstrated elsewhere experimentally that these 
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endotoxin levels do not likely contribute to immune outcomes in our assays [18]; therefore, 
we may gauge that the effects observed in our assays are due to the Echinacea extracts 
themselves and not any contaminating endotoxin. 
Cytokine production by Day 1 extracts 
The abilities of the Day 1 extracts to stimulate cytokine production by peripheral 
blood mononuclear cells (PBMCs) versus media alone (control) are shown in Figures 5-1 
through 5-4. None of the analyses produced significant main effects of storage temperature, 
nor any significant organ-by-temperature interactions. 
Results for IL-1(3 are shown in Figure 5-1. A significant main effect of plant organ 
was found (p < 0.001). In follow-up analyses, IL-1(3 production was found to be 
significantly enhanced by the root tincture as compared to both control and all other tinctures 
(all/? <0.001). 
Results for IL-2 are shown in Figure 5-2. A significant main effect of plant organ 
was found (p = 0.002). Post-hoc analyses indicated that none of the extracts significantly 
altered IL-2 production as compared to control (all p > 0.242). However, flower tinctures 
were significantly different from leaf (p = 0.002), root (p = 0.007), and stem (p = 0.051) 
tinctures. 
Results for IL-10 are shown in Figure 5-3. A significant main effect of plant organ 
was found (p < 0.001). In follow-up analyses, IL-10 production was found to be significantly 
enhanced by root tinctures as compared to control (p = 0.001) and all other tinctures (all p < 
0.001). 
Results for TNF-a are shown in Figure 5-4. A significant main effect of plant organ 
was found (p < 0.001). Post-hoc analyses indicated that root tinctures significantly 
augmented TNF-a production as compared to both control (p < 0.001) and all other tinctures 
(allp < 0.001). Additionally, the flower tinctures showed a trend (p = 0.079) towards 
stimulating more TNF-a production than the stem extract. 
108 
Cytokine production by Day 31 extracts 
Extracts stored at -20°C were again tested under the same experimental conditions for 
their abilities to modulate cytokine production in vitro following one month of storage. 
Results are displayed in Table 5-1. For both IL-1(3 and TNF-a, a significant main effect of 
organ (both p < 0.019) was found; post-hoc analyses indicated that root tinctures alone 
significantly enhanced cytokine production as compared to control (both p < 0.005) and all 
other tinctures (all p < 0.007). For IL-10 there was a trend towards a main effect of plant 
organ (p =0.086) such that the root tinctures significantly augmented IL-10 production as 
compared to both control (p = 0.02) and all other tinctures (all p < 0.039). No significant 
main effects were found for IL-2. 
Cell proliferation by Day 1 extracts 
The abilities of the 4°C Day 1 extracts to stimulate PBMC proliferation versus media 
alone (control) are presented in Figure 5-5. A significant main effect of organ was found (p 
< 0.001). Follow-up analyses indicated that the flower, leaf, and root tinctures were able 
significantly enhanced PBMC proliferation as compared to control (p < 0.001), whereas the 
stem tincture did not (p = 0.237). 
DISCUSSION 
Effects of plant organ 
Results from this study suggest that tinctures prepared from freshly harvested 
Echinacea tennesseensis harbor phytomedicinal properties in vitro, but that these abilities 
vary by plant organ. Production of the cytokines IL-1(3, IL-2, and TNF-a were significantly 
enhanced by E. tennesseensis root tinctures as compared to control, but not by flower, leaf, or 
stem tinctures at both Days 1 and 31 (Figures 5-1, 5-3, 5-4; Table 5-1). None of the tinctures 
modulated IL-2 production at either time point (Figure 5-2; Table 5-1). Considered together, 
these results suggest that E. tennesseensis does harbor cytokine-modulating properties, but 
that these properties are more pronounced in root tissues than in tissues from other organs. 
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Day 1 extracts stored at 4°C were also tested for their ability to modulate PBMC 
proliferation (Fig. 5). Tinctures made from all flower, leaf, and root were able to 
significantly enhance proliferation. In contrast to what we observed with cytokine 
modulation, these results suggest that Echinacea tennesseensis' abilities to modulate PBMC 
proliferation may be found in tissues throughout the body of the plant. 
The immunomodulatory results presented here are congruent with findings published 
previously from our laboratory. In one prior investigation [17], we showed Echinacea 
tennesseensis root tinctures enhanced TNF-a production by young human PBMCs under a 
similar culture scheme. In another previous study [18], we showed similar extracts 
stimulated IL-10 production, but not IL-2 production, from older human PBMCs in an in 
vitro model of influenza vaccination where cells were cultured for 48 h with antigenic 
(influenza) stimulation. The results presented here confirm and extend those findings by 
demonstrating that E. tennesseensis root tinctures are able to augment IL-1(3, IL-10 and TNF-
a (but not IL-2) production. Previously we found that E. tennesseensis root tinctures did not 
significantly enhance PBMC proliferation [17], whereas in this study we report that flower, 
leaf, and root tinctures harbor this ability. These differences are likely due to the larger 
sample size employed in this study. 
Effects of storage temperature 
Our analyses indicated that there were no significant differences between the 
behaviors of tinctures aliquoted from the same stock batch but stored at different 
temperatures for 21 h before being tested for immunomodulatory properties. Previously, we 
investigated the effects of 4 days storage at 4°C on the immunomodulatory properties of root 
infusions and tinctures from several different Echinacea spp. to mimic the storage conditions 
that lay herbalists typically employ [17]. We discovered that extract abilities changed over 
time, but this was sometimes due to endotoxin effects. The results presented here suggest 
that laboratory investigators wishing to study Echinacea extracts as lay herbalists produce 
them might be able to store the extracts at freezing temperatures (i.e., -20°C, -80°C) for 
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short-term purposes without significantly altering their active properties as may be observed 
if they were stored at 4°C without endotoxin. 
Effects of storage time on root tincture activity 
Results from Figures 5-1 through 5-4 and Table 5-1 showed that a month of storage 
did not significantly alter the cytokine-modulating properties of the tinctures tested in this 
investigation. These results suggest that storage of Echinacea tinctures for a short time 
period (one month) does not significantly change their immunomodulatory behaviors. 
Potential role o/Echinacea tennesseensis in modern herbalism 
The genus Echinacea is comprised of nine traditionally recognized species [19]. Of 
these nine, only E. angustifolia, E. pallida, and E. purpurea are used to any appreciable 
extent in the herbal supplement industry. Echinacea tennesseensis exhibits 
immunomodulatory properties similar to some but not all other species of Echinacea. Other 
investigative teams as well as our own have shown that E. angustifolia, E. pallida, and E. 
purpurea differ in both activity and/or phytochemical composition [13-18, 20-26], 
Compared to the other three popular species, Echinacea tennesseensis appears to exhibit in 
vitro immunomodulatory characteristics more similar to E. purpurea than to E. angustifolia 
or E. pallida. The findings presented here, alongside previous antiviral [16], immune [17, 
18], and phytochemical [14-16] data, suggest that E. tennesseensis may be of use in modern 
herbalism. 
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Table 5-1. Cytokine production from human PBMC treated with Echinacea tennesseensis 
extracts stored for one month at -20°C. 
IL-ip IL-2 IL-10 TNF-a 
Control 9.14 ±0.83= 1.24 ±0.5 7.7 ±0.26 20.2 ± 0.08 
Root 78.34 + 41.4* 1.49 ±0.35 355.27 ± 141.03' 184.22 ±79.11* 
Stem 9.17 + 0.55 1.54 ±0.46 11.86 ± 2.71 20.32 ±0.19 
Leaf 18.1 + 7.31 0.92 ±0.52 35.03 ±20.01 26.28 ± 5.35 
Flower 12.21 ±2.89 1.90 ±0.18 33.12 + 8.26 24.76 ±2.53 
3 Values are organized as (pg/mL; mean ± standard error). Asterisks indicate statistical significance ( p  <  0.05). 
Daggers 0) indicate trends towards statistical significance (0.05 <p <0.1). 
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Figure 5-1. Interleukin-lp production by human PBMC cultures stimulated with Echinacea 
tennesseensis extracts. Bars represent means ± standard errors. Asterisks indicate statistical 
significance compared to control (p < 0.05). 
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Figure 5-2. Interleukin-2 production by human PBMC cultures stimulated with Echinacea 
tennesseensis extracts. Bars represent means ± standard errors. Asterisks indicate statistical 
significance compared to control (p < 0.05). 
117 
100 -i 
en 
Q_ 
80 -
60 -
40 -
20 -
T I 
X 
con 4° -20° -80° 4° -20°-80° 4° -20°-80° 4° -20°-80' 
root stem leaf flower 
Figure 5-3. Interleukin-10 production by human PBMC cultures stimulated with Echinacea 
tennesseensis extracts. Bars represent means ± standard errors. Asterisks indicate statistical 
significance compared to control (p < 0.05). 
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Figure 5-4. Tumor necrosis factor-a production by human PBMC cultures stimulated with 
Echinacea tennesseensis extracts. Bars represent means + standard errors. Asterisks indicate 
statistical significance compared to control (p < 0.05). 
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Figure 5-5. Proliferation of human PBMC stimulated with fresh Echinacea tennesseensis 
extracts. Bars represent means ± standard errors. Asterisks indicate statistical significance 
compared to control (p < 0.05). 
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CHAPTER 6. PHENETIC COMPARISON OF SEVEN ECHINACEA SPP. BASED 
ON IMMUNOMODULATORY CHARACTERISTICS 
A paper submitted to Economic Botany1 
David S. Senchina,2'3 Lex E. Flagel,4 Jonathan F. Wendel,4 Marian L. Kohut2,3 
ABSTRACT 
The purpose of the present investigation was to compare similarities and differences 
in immune response among Echinacea species, commonly used to treat upper respiratory 
infections. The investigation involved two components: acquisition of immunomodulatory 
data reported here for the first time, and combined phenetic analysis of these data along with 
previous reports. Experimental data were obtained by stimulating human PBMC in vitro 
with extracts from Echinacea spp. and assaying production of three cytokines (interleukin-1 (5 
[IL-1(3], interleukin-2 [IL-2], and tumor necrosis factor-a [TNF-a]). Phenetic analyses were 
employed to compare responses across the entire data set, including UPGMA (Unweighted 
Pair Group Method with Arithmetic Mean) and neighbor-joining methods. In the immune 
experiments conducted for this investigation, E. angustifolia, E. paradoxa, E. purpurea, E. 
simulata, and E. tennesseensis extracts significantly augmented IL-1 (3 and TNF-a 
production, whereas no extracts significantly modulated IL-2. All phenetic methods 
produced similar dendrograms, revealing two species pairs (E. angustifolia + E. simulata and 
E. pallida + E. sanguinea) where both species cluster tightly and have similar immune-
response profiles. These two species-pairs are maximally dissimilar from each other. The 
remaining species (E. paradoxa, E. purpurea, and E. tennesseensis) occupy intermediate 
positions in the dendrogram. Our results suggest that Echinacea spp. act heterogeneously on 
immune function. The utility of these data for science and industry is discussed. 
1 Submitted December 30, 2005; accepted with revisions April 4, 2006. 
2 Immunobiology Program, Iowa State University 
3 Department of Health and Human Performance, Iowa State University 
4 Department of Ecology, Evolution, and Organismal Biology, Iowa State University 
121 
INTRODUCTION 
In modern herbal medicine, Echinacea is most commonly employed for treating 
upper respiratory infections, particularly viral infections such as colds (rhinoviruses) and 
influenza [1], However, data are in conflict regarding its efficacy, with some studies 
supporting effectiveness [2-4] and others discounting it [5-7]. 
The vast majority of immunomodulatory studies of Echinacea have centered on three 
of the nine traditionally-recognized species: E. angustifolia, E. pallida, and E. purpurea [8]. 
By comparison, other Echinacea species have been neglected, presumably because of 
economic factors, as the aforementioned species are the ones most frequently employed in 
commercial phytomedicinal preparations. Considerable research has been aimed at 
elucidating the phytochemical profiles of Echinacea species, but the relationship between 
phytochemistry and medicinal function has yet to be demonstrated satisfactorily [8]. Studies 
of immune function, both in vitro and in vivo, remain the methods of choice for evaluating 
immunomodulatory efficacy. Our laboratory [9-11], as well as others [12], have 
demonstrated that the remaining species may also harbor immunomodulatory properties. 
A comparison of immunomodulatory properties across Echinacea species has yet to 
be conducted; thus, it is presently unclear how Echinacea species compare to one another 
regarding potential immunomodulatory characteristics. In the present investigation, we 
demonstrate how in vitro models of immune function may be used to systematically 
investigate the similarities and differences in such functions across seven species of the 
genus Echinacea. Our report encompasses full development of the investigation from novel 
experimental data acquisition through final analyses. 
MATERIALS AND METHODS 
Experimental data collection 
All procedures involving human subjects were pre-approved by the Iowa State 
University Internal Review Board for human subject's research. Peripheral blood 
mononuclear cells were harvested from fifteen healthy human young adult donors using 
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methods previously described [9], Cells were adjusted to a concentration of 1.0 x 106 
cells/mL and cultured for 24 hours with extracts described previously [9] from seven 
Echinacea species (E. angustifolia [ANG], E. pallida [PAL], E. paradoxa [PAR], E. 
purpurea [PUR], E. sanguinea [SAN], E. simulata [SIM], and E. tennesseensis [TEN]) and 
compared to control [CON]; however, in contrast to the study reported earlier [9], the 
extracts employed here had been stored at -20°C for one month before being used in this 
investigation. Supernatants were harvested and tested for production of interleukin-1 (3 (IL-
1 p), IL-2, and tumor necrosis factor-a (TNF-a) via ELISA (BD Biosciences, Pharmingen, 
San Diego, CA). Statistical analyses employing a general linear model of repeated measures 
were performed in SPSS (Chicago, IL). 
Data matrix construction 
A data matrix was constructed for use in the phenetic analysis. This matrix was 
derived from previous investigations [9-11] on PBMC proliferation and cytokine production 
as well as unpublished data on cytokine production by Echinacea preparations presented 
here. Day four data for interleukin-10 and tumor necrosis factor-a from study [9] were 
excluded due to possible effects of contaminating endotoxin. We elected to use only studies 
from our own laboratory as this eliminated variability due to differences in experimental 
methodologies. Individual immune outcomes were treated as distinct characters. In total, 
25 characters were employed in the matrix (Table 6-2). Characters 1-22 represent previously 
published data, whereas characters 23-25 represent original data from Table 6-1. 
For each character, the effect of the Echinacea species was compared against a 
control; statistical methods for this comparison varied by study and can be found in the 
individual papers. The control was designated as having a character state of "0". Within a 
given immune parameter, species that statistically augmented the outcome as compared to 
the control were assigned a state of "1"; likewise, species that statistically diminished the 
outcome were assigned a state of "2." Thus, for each immune outcome, there were three 
possible unordered and equidistant character states. 
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Phenetic analysis 
Immune response data were converted to the "NEXUS" data format and imported 
into the software program Phylogenetic Analysis Using Parsimony (PAUP*) version 4.0b 10 
[13]. Data were treated as unordered and because the mechanisms underpinning the immune 
responses are unknown, all immune response categories were given equal weight. A 
distance matrix was constructed using the mean pairwise character differences adjusted for 
missing data. This distance matrix was then subjected to both neighbor-joining and 
clustering analyses, the latter using the unweighted pair group method with arithmetic mean 
(UPGMA) method, and final dendrograms were produced in R [14]. 
RESULTS 
Experimental data 
We tested Echinacea extracts from seven species that had been stored for one month 
at -20°C for their ability to modulate interleukin-1 p (IL-lp), IL-2, and tumor necrosis factor-
a (TNF-a) from peripheral blood mononuclear cells (PBMCs) of young adults. Results are 
presented in Table 6-1. Extracts from E. angustifolia, E. paradoxa, E. purpurea, E. simulata, 
and E. tennesseensis were all able to significantly augment IL-lp and TNF-a production. 
None of the extracts significantly altered IL-2 production, compared to the control. 
Phenetic analysis 
The data matrix used in the phenetic analysis is given in Table 6-2. While some 
immune parameters appear multiple times on the table, each is distinct due to differences in 
extract preparation and storage methods, subject demographics, or cell culture protocols 
between studies; these differences also may explain apparent contradictions in results. For 
example, differences in IL-2 outcomes may be due to the human subjects used: extracts had 
no effect on IL-2 production in young subjects, however they appeared to diminish IL-2 
production in older adults and diminished capacity to produce IL-2 is known to be a 
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consequence of aging (reviewed in [15]). Similarly, in older adults, ethanol tinctures from E. 
pallida suppressed IL-10 production, whereas similar tinctures had no effect or augmented 
IL-10 production in young adults. TNF-a production was enhanced only when extracts had 
not undergone long-term storage. 
The data matrix was subjected to multivariate analysis as described (see Methods), 
yielding the dendrogram shown in Figure 6-1. 
DISCUSSION 
In this report, we validate that data from immunological investigations of seven 
Echinacea species may be analyzed phenetically to compare similarities and differences 
among species. Our demonstration included the acquisition of original data. We consider 
each of these aspects separately below, as well as possible applications. While we used 
Echinacea in this report, the system outlined here might be applicable to other medicinal 
plant taxa. 
Consideration of original data 
Echinacea extracts used in this study either had no effect on or stimulated production 
of the cytokines surveyed (Table 6-1). Five species (E. angustifolia, E. paradoxa, E. 
purpurea, E. simulata, and E. tennesseensis) stimulated production of IL-ip and TNF-a, but 
did not augment IL-2 production. Two other species, E. pallida and E. sanguinea, did not 
influence levels of any of these three cytokines. Although the extracts tested here are the 
same as those reported elsewhere [9], a direct comparison between the two studies is difficult 
due to numerous differences in experimental design (mode of stimulation, extract time of 
storage). 
IL-lp and TNF-a are cytokines produced during the inflammatory response by cells 
of the innate immune system such as macrophages [16, 17]. Consequently, it is not 
surprising that the effects of the different Echinacea species on IL-lp and TNF-a were 
similar. Our findings that Echinacea tinctures augmented production of these cytokines are 
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consistent with reports from both human [18-20] and rodent [21-24] model systems; 
however, two teams found no effect of Echinacea extracts on these cytokines [25, 26]. These 
differences may be due to species selection, plant organ selection, extraction method, or other 
experimental choices as discussed above. 
In contrast, IL-2 is a marker of T-cell activation associated with adaptive immunity 
[27]. Our results are consistent with those from previous reports [22] but in contrast with 
other reports using aerial parts showing application of Echinacea extracts to cell cultures 
induces production of IL-2 in vivo [21, 28]. Again, these differences are likely to due 
differences in experimental design, such as choices of model organism, extract type, and 
species selected. 
These results also suggest that Echinacea may influence innate immunity to a greater 
extent than adaptive immunity based on the limited number of parameters that were 
evaluated. This observation is consistent with previous findings from our lab, as well as 
findings from other investigators [2, 18]. 
Phenetic analysis 
The result of the phenetic analysis is shown in Figure 6-1. Echinacea pallida and E. 
sanguinea clustered tightly together and separate from all other taxa. Among the remaining 
five species, E. angustifolia and E. simulata were more similar to one another than to the 
remaining three species E. paradoxa, E. purpurea, and E. tennesseensis. Finally, the immune 
response profiles of E. paradoxa, E. purpurea, and E. tennesseensis were approximately 
equidistant from each other and from the E. angustifolia+E. simidata species-pair. One key 
observation is that the three species employed commercially (E. angustifolia, E. pallida, and 
E. purpurea) were widely separated from one another on the dendrogram. 
Possible applications for phytomedicine 
Multivariate relationships among species-specific immune responses may help inform 
phytomedicinal investigations. For example, it can be seen from Table 6-2 that Echinacea 
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pallida tends to exhibit no or suppressive immune modulation, whereas E. angustifolia tends 
to exhibit mostly enhancing effects on immune function. Our dendrogram suggests that E. 
angustifolia and E. pallida have very different immunomodulatory capabilities from one 
another. It also suggests that if an immunosuppressive effect is desirable, species such as E. 
pallida and E. sanguinea should be favored; likewise, if enhanced immune responses are 
desired, species such as E. angustifolia and E. simulata should be selected. It is important to 
stress that these data are based on the testing of only ethanol decoctions and water infusions 
from a representative sampling of species and accessions; the interpretation is thus limited to 
these extract types. Different immunomodulatory properties may be obtained by different 
extraction methods from different accessions. 
Our results suggest that different Echinacea spp. act heterogeneously on immune 
function. Scientists studying Echinacea frequently report findings from only one species. 
The data presented here indicate that there is not one "representative" species of Echinacea, 
and that immune effects are highly contingent on species selection, extraction technique, and 
extract storage conditions. This has important ramifications for further investigations of the 
immunomodulatory activity. As reviewed above, studies disagree as to Echinacea's 
effectiveness in the treatment of respiratory infections. Perhaps, as our results suggest, these 
discrepancies may arise in part due to investigators employing different species. 
Possible applications for botanical supplements industries 
Our findings of heterogeneous immune activity among species of Echinacea may be 
important to the botanical supplements industry. Currently, E. angustifolia, E. pallida, and 
E. purpurea are used in most Echinacea preparations, either alone or in combination. 
Species selection may be a potentially critical factor in the manufacture of Echinacea 
supplements and should be determined based on desired immune outcome. Further, this 
analysis suggests that many species of the genus (in particular, E. sanguinea and E. simulata) 
might by worthy of cultivation for phytomedicinal preparations, again based on desired 
immune outcome. 
127 
Immune responses and evolutionary history of the genus 
While our phenetic analysis do not make any statements regarding evolutionary 
relationships between the seven taxa studied here, it is instructive to compare our results 
against two currently competing taxonomic interpretations of the genus. The traditional 
treatment constructed by McGregor [29], and the treatment employed in this study, identifies 
9 species in the genus. However, one investigator [30] has more recently proposed the genus 
be considered as only 4 species. Both treatments are based on morphological characters. 
Binns' treatment groups E. angustifolia, E. pallida, E. sanguinea, E. simulata, and E. 
tennesseensis sensu McGregor as five varieties within the species E. pallida. However, if 
these five taxa are compared on our dendrogram, we see that they do not cluster as a 
monophyletic group on the tree; rather, they are interspersed throughout the dendrogram. 
Additionally, in our phenetic analysis, E. purpurea, which Binns separated distinct from all 
other taxa, E. purpurea is distant from all other taxa with respect to overall levels of 
dissimilarity on the dendrogram. Taken together, this phenetic analysis appears more 
congruent with the taxonomic treatment proposed by McGregor. 
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Table 6-1. Results from immune assays. 
IL-1(3 IL-2 TNF-a 
CONa 10.3 ±0.68*" 2.91+0.62 8.56 ±0.35 
ANG 242.78 + 36.84* 2.54 ±0.42 697.29 + 65.81* 
PAL 10.59 + 0.7 2.61 ±0.79 47.92 ± 16.69 
PAR 41.34 + 7.97* 2.92 + 0.64 324.23 ± 78.86* 
PUR 215.60 + 32.61* 2.48 ±0.45 697.32 + 64.27* 
SAN 16.96 + 2.65 2.35 + 0.51 143.6 + 45.9 
SIM 49.08 ± 11.91* 2.79 ±0.46 482.62 ±75.76* 
TEN 44.95 ± 11.65* 3.22 + 0.85 248.47 ±57.12* 
a CON represents control values (no extract added); species abbreviations are given in the Methods. 
b Values represent mean cytokine production in pg/mL ± standard errors. Asterisks indicate values statistically 
significantly different from control. 
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Table 6-2. Data matrix used in phenetic analysis using data generated previously (characters 
1-22) as well as unpublished data (characters 23-25). 
Source 
[9] 
Immune Parameter 
(Extract Type) 
ANGa PAL PAR PUR SAN SIM TEN 
1. TNF-a, Day 1 (OH)b r N t N N 
2. TNF-a, Day 1 (CW) N T t N N 
3. TNF-a, Day 1 (HW) N N t N N 
4. IL-10, Day 1 (OH) t N N N N 
5. IL-10, Day I (CW) t N N N N 
6. IL-10, Day 1 (HW) t N t N N 
7. IL-12, Day 1 (OH) t N N N N 
8. IL-12, Day 1 (CW) t t N N N 
9. IL-12, Day 1 (HW) N N N N N 
10. IL-12, Day 4 (OH) N N ; N I 
11. IL-12, Day 4 (CW) N N T N t 
12. IL-12, Day 4 (HW) N N N N t 
13. Prolif, Day 1 (OH) N N N N N 
14. Prolif, Day 1 (CW) N N N N N 
15. Prolif, Day 1 (HW) N N N N N 
a Species abbreviations are given in Methods. 
b Extract type abbreviations are as follows: OH = 50% ethanol/50% water tincture, CW = cold water infusion, 
HW= hot water infusion. 
c For species outcomes, the symbol "T" indicates significant enhancement of cytokine production compared to 
the control, whereas the symbol "4" indicates significance decrease in cytokine production compared to the 
control; "N" indicates "no change" compared to control. Blanks represent unavailable data. 
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Figure 6-2. (continued) 
Source Immune Parameter 
(Extract Type) 
ANG PAL PAR PUR SAN SIM TEN 
[H]  16. IL-2 (OH) : 4 1 i I 4 
17. IL-10 (OH) T : N t t N t 
18. IFN-y (OH) N N N N 
[10] 19. Prolif (OH) t t t N t t t 
20. TNF-a (OH) N N N N N N N 
21. IL-10 (OH) t t t t N N t 
22. IL-12 (OH) N N N N N N 4 
Present 23. IL-ip (OH) t N t T N t t 
study 
24. IL-2 (OH) N N N N N N N 
25. TNF-a (OH) Î N t t N t t 
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Figure 6-1. An UPGMA dendrogram showing results of phenetic analysis of the 
immumodulatory properties of seven species of Echinacea. Species abbreviations are given 
in methods. Taxa linked at nodes with lower levels of dissimilarity have greater overall 
similarity in their ability to modulate the immune properties studied here. 
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CHAPTER 7. GENERAL CONCLUSIONS 
DISCUSSION 
In this dissertation we examined how the immunomodulatory capabilities of 
Echinacea spp. extracts were influenced by three different factors (species selection, 
extraction techniques, and storage conditions) in order to develop a better picture of the 
medical botany of the genus Echinacea. Chapter 1 presented a framework for the 
dissertation by reviewing the literature, establishing research foci, and generating 
experimental questions and hypotheses to address each of the foci. Chapters 2-6 presented 
the results of our experiments. We can take the data from Chapters 2-6 and apply them back 
to our three research foci to answer our experimental questions and evaluate our hypotheses. 
(1) Effects by species 
Our research question: What is the extent of phytomedicinal activity in the genus (i.e., 
which species harbor particular properties as compared to others)? We hypothesized that 
each individual Echinacea spp. would perform heterogeneously compared to other species 
across a broad panel of immune assays. An underlying assumption of this hypothesis was 
that a given individual species would perform in a somewhat consistent fashion between 
experiments, yielding a distinct "immunological profile" compared to others. Chapter 2 
focused on E. angustifolia, E. pallida, E. purpurea, E. sanguinea, and E. tennesseensis, 
whereas Chapters 3-6 included these species as well as E. paradoxa and E. simulata', thus, 
seven different species were investigated in this dissertation. 
Our in vitro immune screenings relied on two main peripheral blood mononuclear cell 
(PBMC) functional assays: cytokine production (including interleukin-1(3 [IL-1(3], IL-2, IL-
10, IL-12, interferon-y [IFN-y], and tumor necrosis factor-a [TNF-a]) and proliferation. 
These parameters are important in the context of immune response to viral infection, for 
which Echinacea preparations are taken most commonly today. 
Consistent with our hypothesis, we found that each species had its own "signature" of 
immunomodulatory activity, but that this signature was influenced by extract preparation and 
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storage factors (these will be discussed in the following section). These results are best 
represented in Table 6-2. Using Table 6-2, we were able to conduct a phenetic analysis 
(Chapter 6) of immunomodulatory properties across genus members. We found two species-
pairs wherein both members of the pair behaved more similarly to each other than to other 
species: Echinacea angustifolia—E. simulata and E. pallida—E. sanguinea. Further, these 
two species-pairs were more dissimilar to one another than to any of the other species. The 
three remaining species (E. paradoxa, E. purpurea, and E. tennesseensis) were dissimilar to 
each other and to the species pairs, possessing intermediary immunomodulatory properties. 
We endeavored to apply our findings from focus 1 to three fronts, (a) We wanted to 
address the lack of cross-genus comparisons. All five research chapters represented a 
contribution to this arena; these efforts culminated in the analysis presented in Chapter 6, 
which represents the first cross-genus analysis of immunomodulatory properties for the 
genus, (b) We wanted to provide information to both commercial manufacturers and 
consumers of Echinacea spp. phytomedicines as regards the potential utility of each species 
for particular medical conditions. It is curious to note that the three species used most 
prolifically in commercial supplements (Echinacea angustifolia, E. pallida, and E. purpurea) 
behaved differently from one another in our assays, suggesting that the three species should 
not be assumed to have homogeneous effects on the immune system (currently, most of the 
industrial sector treats these species as the same). From a medical standpoint, our results 
suggest that the medicinal benefits of Echinacea are contingent upon the species selected. 
Thus, any use of Echinacea medicinally should be done with consideration for the desired 
immune outcome, followed by the selection of the most appropriate species. For example, 
E. angustifolia seems to be the most stimulatory of the species, whereas E. pallida tends to 
exhibit the most repressive properties of all the species. All species tested exhibited some 
form of immunomodulatory activity, (c) We wanted to possibly explain some of the pre­
existing discrepancies in the scientific literature regarding the efficacy of Echinacea. Many 
scientific reports give only Echinacea sensu lato as their plant source. Our results suggest 
that comparing studies without considering species effects may be hazardous and misleading. 
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What may seem to be discrepant results in the scientific literature may simply be due to 
different species employed. 
(2) Effects by extraction techniques 
Our research question: Are lay herbalist techniques capable of producing extracts 
with immunomodulatory properties? Within this question, there were two separate aspects of 
lay herbalist methods that we wanted to explore: differences in extraction techniques 
themselves, but also differences in extracts produced from fresh versus dry material. 
Our first working hypothesis for this research focus was that both infusions and 
tinctures produced using lay herbalist methods would be efficacious in modulating some of 
the immune parameters in our model. We employed lay herbalist techniques to produce all 
of extracts for Chapters 2-6; thus, the results from all five chapters may be considered in 
addressing this focus. Consistent with our hypothesis, we found that lay herbalist methods 
were capable of yielding extracts that had experimentally consistent immunomodulatory 
activities in human in vitro PBMC models. Both infusions (Chapter 2) and tinctures 
(Chapters 2-6) yielded activities, although tinctures were stronger performers. It was this 
fact that prompted us to utilize only tinctures in subsequent investigations. Curiously, in one 
assay (Chapter 2), the same species could have opposing effects on IL-12 production 
contingent on whether the extract was a tincture (suppressive effect) or an infusion 
(enhancing effect). 
An unexpected experimental confounder that arose during the first investigation 
(Chapter 2) was endotoxin produced by contaminating bacteria (such as those borne on the 
roots of the plant). Endotoxin is a known mitogen. However, the gut filtering/altering 
process is circumvented in in vitro experimentation such as employed here. Therefore, it was 
important to ascertain whether the effects observed in our in vitro assays were due to 
Echinacea spp. constituents or bystander endotoxin. We employed statistics to address this 
initially (Chapter 2) and found that endotoxin was not a factor in our freshly prepared 
extracts, but did impact our results following storage for four days at 4°C. However, this 
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technique was more theoretical than experimental, and we desired a more scientifically based 
approach to investigate endotoxin effects. Therefore, we cultured PBMC with varying levels 
of diluted endotoxin under our same experimental conditions (Chapter 3). We discovered 
that endotoxin levels even 10x higher than the final endotoxin concentrations in our extract-
treated wells did not alter immune parameters to any significantly different extent than 
control (no endotoxin) wells. This suggested that our experimental outcomes were not due to 
the stimulatory effects of bystander endotoxin. 
Our second hypothesis for this research focus was that drying the plant material for 
over a year would result in a complete loss of immunomodulatory activity, possibly due to 
degeneration of bioactive molecules. It was a distinct possibility that our drying regimen (16 
months) may have completely abrogated any immunomodulatory activity due to a chemical 
change in bioactive constituents. However, when we tested dried roots in an in vitro older 
adult model of influenza vaccination (Chapter 3), we found them capable of augmenting IL-
10, reducing IL-2, and had little or slightly reducing effects on IFN-y. These data suggest that 
drying does not destroy the immunomodulatory properties of Echinacea spp. root material. 
We endeavored to apply our findings from focus 2 to five fronts, (a) It was our goal to 
validate or refute the potential utility of lay herbalist techniques to produced extracts with 
immunomodulatory properties. Chapter 2 was the first scientific study to demonstrate that 
extracts prepared using lay herbalist techniques harbored immunomodulatory properties in in 
vitro cell culture models. Subsequent studies (Chapters 3-6) buttressed this conclusion. 
These findings could potentially support the practice of lay herbalism using Echinacea, and 
may also validate historical uses for the genus. From a scientific standpoint, we 
demonstrated that lay herbalist extraction techniques, when performed under controlled 
laboratory conditions, can yield products amenable to laboratory investigation. Further, we 
showed that any contaminating endotoxin in our diluted extracts was not at a significant 
enough concentration to influence our immune outcomes. Hopefully, these findings will 
encourage other investigators to also examine extracts made in the lay herbalist fashion, (b) It 
was our goal to compare differences in immunomodulatory properties between infusions and 
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tinctures. As demonstrated above, tinctures tended to be more active and more 
heterogeneous in their activities than either hot or cold water infusions, (c) It was our goal to 
ascertain the effects of long-term drying on Echinacea phytomedicinal properties. Our 
findings suggest that drying changes, but does not necessarily destroy, the phytomedicinal 
properties of Echinacea preparations, (d) It was our goal to provide practical information to 
consumers and manufacturers about extraction techniques. Our findings suggest that 
individuals practicing lay herbalist techniques might derive more immunomodulatory 
benefits by using tinctures versus infusions, (e) It was our goal to possibly explain some of 
the pre-existing discrepancies in the scientific literature regarding the efficacy of Echinacea. 
Many scientific reports state only vague descriptions (or worse, only proprietary names, 
giving no hint of extraction technique) of extract method. Our results suggest that specific 
extraction techniques are important considerations when comparing between scientific 
studies, as different extract types exhibit contrasting properties. Comparing between extract 
types may be misleading. 
(3) Effects by storage conditions 
Our research question: How do different extract storage conditions, including those 
employed by both lay herbalists and scientific investigators, influence extract 
immunomodulatory activity? Our working hypotheses regarding extract storage conditions 
touched on both temperature and time as being important variables. 
Regarding temperature, we hypothesized that extracts stored at different temperatures 
(e.g., 4°C, -20°C, and -80°C) would exhibit heterogeneous immunomodulatory activities. 
Chapter 5 provides the only study where aliquots were simultaneously stored at three 
different temperatures and then tested for immunomodulatory activity 21 hours later. None 
of the aliquots stored at different temperatures were significantly different from one another 
in our assays. However, the storage period was very short, and it is possible that differences 
become apparent with longer time lengths of storage. It is more difficult to compare results 
regarding storage temperature across our five studies, as other experimental variables (such 
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as age of PBMC donor, culture model characteristics, and extract source) also varied between 
these studies. Additionally, it becomes difficult to tease apart differences due to temperature 
vs. differences due to time. Nevertheless, we may proffer the observation that extracts stored 
at all three temperatures, 4°C (Chapters 2 and 5), -20°C (Chapters 3-6), and -80°C (Chapter 
5) demonstrated some immune-modulating activities. 
Regarding time, we hypothesized that aliquots stored for longer lengths of time would 
exhibit reduced immunomodulatory activity as compared to aliquots stored for shorter 
lengths of time. Overall, we found that the data do not agree with our hypothesis; rather, 
they suggest that aliquots stored for longer lengths of time exhibit different 
immunomodulatory activities compared to aliquots stored for shorter periods, not necessarily 
reduced activity. Several key comparisons demonstrate this point well. We chose to 
examine three different time storage regimens: four days at 4°C (representing the maximum 
time span that most lay herbalists retain Echinacea spp. extracts at refrigerator temperatures), 
one month at -20°C and -80°C (to examine the effects of short-term storage under laboratory 
conditions), and two years at -20°C (to examine the effects of long-term storage under 
laboratory conditions). 
In the four-day comparison, we found that extract activities changed with time, 
though endotoxin was a confounding factor (Chapter 2). The only immune variable we could 
directly compare at the two time points was IL-12, and we found that the specific extracts 
that augmented IL-12 production changed from Day 1 to Day 4. This suggests that short-
term storage at 4°C results in altered extract activities, possibly due to chemical changes in 
the bioactive molecules from Echinacea, or due to contaminant microbial activity. 
In the one-month comparison, we examined the cytokine-modulating abilities of 
identical extracts both pre- and post-storage for one month at -80°C (Chapter 5). No 
differences in cytokine-modulating properties were observed, suggesting there was no 
significant effect of one-month storage. Chapters 3 and 6 also tested the same extracts fresh 
(within 4 days of preparation) and after one month of storage at -20°C. However, the two 
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models used between the two experiments are sufficiently different to make a direct 
comparison between the two highly tenuous. 
In the two-year comparison, the same extracts were tested in the same assays both 
fresh (Chapter 2) and after being stored for two years at -20°C (Chapter 4). For this 
comparison, it is important to focus only on the data from the unvaccinated individuals in 
Chapter 4, as they represent the appropriate comparison group to Chapter 2 subjects. We 
found that the aged extracts still harbored immunomodulatory activities, though they were 
different from the activities demonstrated when fresh. For example, fresh extracts did not 
modulate PBMC proliferation, but after 2 years storage, all species demonstrated some 
ability to augment proliferation. 
We endeavored to apply our findings from focus 3 to four fronts. The first two need 
to be considered together, (a) We wanted to determine the effects of storage temperature on 
the immunomodulatory properties of extracts, (b) We wanted to determine the effects of 
storage time on the immunomodulatory properties of extracts. Our results suggest that 
storage temperature and time may impact on observed immunomodulatory properties 
separately, but that there is also interplay between these two factors. Storage at 4°C 
potentially permits endotoxin to become a confounding variable in immunomodulatory 
assays. Extracts stored at -20°C or -80°C do not suffer from this problem and do not appear 
to differ from one another over short time periods of storage. Phrased another way, even 
short storage times at super-zero temperatures (i.e., 4°C) results in changes in extract activity, 
whereas long (i.e., years) storage times at sub-zero temperatures (i.e., -20°C or -80°C) are 
needed before changes are observed, (c) We wanted to provide practical information to both 
consumers and lay and commercial manufacturers about the effects of these conditions on the 
potential performance of extracts. Our results suggest that both consumers and 
manufacturers need to be cognizant of extract storage conditions, particularly for 
preparations stored at temperatures above freezing for short time spans, (d) We wanted to 
possibly explain some of the pre-existing discrepancies in the scientific literature regarding 
the efficacy of Echinacea. Laboratory investigators typically generate Echinacea extracts in 
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large batches and store them for long periods of time. Storage regimens differ in both time 
and temperature across labs, and are (exceedingly) rarely reported in the literature. Our 
results suggest that storage conditions are important variables in determining extract 
performance. Thus, comparing studies using frozen extracts may be misleading if attention 
isn't given to specific protocols; however, this is next to impossible given the current lack of 
details reported within individual studies. 
CONCLUSIONS AND SIGNIFICANCE 
General conclusions 
Taken together, some general conclusions may be made from these data regarding the 
medical botany of the genus Echinacea. All of the seven Echinacea spp. tested harbored 
immunomodulatory properties, but they were heterogeneous between species. Extract 
factors (such as extraction technique, drying time of plant material before extraction, extract 
storage temperature, and extract storage time) are all important factors that work together to 
determine the immunomodulatory properties of a particular preparation. Lay herbalist 
techniques yield extracts with immunomodulatory properties in vitro. Factors such as 
species selection, extraction technique, and extract storage conditions need to be reported in 
scientific articles to allow for a more accurate comparison of findings across studies. From 
these results, we can validate the overarching hypothesis of the dissertation, namely, that 
factors such as species selection, extraction technique, and storage conditions are all critical 
in determining the immunomodulatory properties of Echinacea spp. preparations. 
Echinacea in the context of viral infection 
A key feature of our experimental design was that all the immune parameters we 
tested are known to be important in the context of infection. Further, two of our 
investigations (Chapters 3 and 4) were performed using PBMC from donors vaccinated with 
that year's respective trivalent influenza vaccine. Echinacea spp. preparations are taken most 
widely today to treat upper respiratory infections such as colds and influenza. Therefore, we 
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may apply our data to the question of whether or not Echinacea may be useful in treating 
infections, bearing in mind that vaccination can serve only as an experimental proxy for 
actual infection. 
Our results suggest that Echinacea preparations do not seem to have much direct 
impact on viruses directly or the viral infection-associated immune responses. However, 
they do seem to strongly augment anti-inflammatory activities (such as IL-10 production) of 
the immune system. The most plausible explanation of these findings is that Echinacea does 
not help in the viral battle per se, but rather can help quell immune responses to viruses (i.e., 
through production of anti-inflammatory molecules) and speed symptom resolution (in a 
collective sense). This hypothesis is consistent to what other researchers have found [1,2], 
and may also corroborate the anecdotal records of Echinacea's benefit in resolving viral 
infections [3]. 
It is also important to point out that we obtained different results when Echinacea was 
used as the sole stimulant, versus when Echinacea was used in conjunction with an antigen 
(i.e., influenza virus in the vaccination studies). Thus, while Echinacea may not be directly 
antiviral, the presence of virus may alter the immunomodulatory properties of Echinacea 
extracts through as yet unknown mechanisms. 
LIMITATIONS OF FINDINGS 
The data presented in Chapter 2-6 have several limitations. Four are of particular 
note and are discussed briefly below. 
All of our models were in vitro models. Despite their many advantages, in vitro 
experiments do have several limitations. One is their artificiality - as they occur outside the 
true organismal context, in vitro assays don't take into account all of the physiological 
variables that would interact in an actual organism. With Echinacea specifically, in vitro 
findings are not always substantiated in human subjects [4], In the context of Echinacea, in 
vitro assays circumvent the normal digestion procedures that Echinacea supplements would 
experience upon ingestion. This is a pertinent point when one considers purported bioactive 
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molecules: the gut breaks down substances like polysaccharides, but with in vitro cultures, 
they are exposed directly (without gut modification) to the target cells. Thus, the effects seen 
by polysaccharides in vitro may not be good proxies for inferring in vivo effects [5], 
Our experiments focused mainly on tinctures, and, to a lesser extent, infusions. We 
did not explore other types of extracts such as decoctions. These techniques may also yield 
active extracts. It is important to interpret our data in the context of respective extract type. 
Also, many consumers use proprietary extracts for ease of convenience; these results may not 
be directly applicable to them. However, we elected not to use proprietary extracts as a 
recent study showed all commercial extracts did not contain contents as claimed by the 
manufacturer [6]. Thus, we would not have been able to vouch for the chemical composition 
of proprietary extracts. 
With the exception of Chapter 3, none of our experiments included a biochemical 
component. Thus, most of our findings cannot speak directly towards the 
immunomodulatory properties of specific molecules. 
Finally, due to a lack of material availability, we were unable to explore the 
immunomodulatory properties of two of the nine Echinacea species, E. atrorubens and E. 
laevigata (the latter representing a second endangered species from the genus). 
RECOMMENDATIONS FOR FUTURE RESEARCH 
While the data presented here are novel and represent the first steps towards the 
questions posed previously, they represent only a foundation from which further endeavors 
can be launched. We can again return to our three research foci as an organizing framework 
to explore future directions. Some of the recommendations directly address limitations as 
outlined previously. 
(1) Effects by species 
Two main recommendations can be made under this heading. First, the two species 
neglected in this dissertation (E. atrorubens and E. laevigata) need to be examined using 
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these same assays. These two species may harbor their own unique suite of characteristics 
that are potentially useful medicinally. Second, attention needs to be given to differences 
with subspecies (cultivars, varieties) of single species. For example, E. angustifolia is 
recognized as having two subspecies: E. angustifolia var. angustifolia, and E. angustifolia 
var. strigosa. Similarly, E. paradoxa also has two subspecies: E. paradoxa var. neglecta and 
E. paradoxa var. paradoxa. The genetic relationships between Echinacea species and 
subspecies are presently unclear, but under investigation. Preliminary data suggest that there 
may be more intraspecies than interspecies diversity for some comparisons; in fact, 
geographic (and more specifically, habitat) origin may be an important factor in a given 
plant's phytomedicinal properties. Thus, it is plausible that certain subspecies may be more 
dissimilar to one another than they are to separate species either due to genetic or 
environmental factors, and this has important ramifications for phytomedicinal use. 
(2) Effects by extraction techniques 
Two main recommendations can be proffered. First, extract types other than 
infusions and tinctures should be explored. It is possible that other methods yield extracts 
with different properties. Second, our findings need to be extended to animal and then 
human models. In vitro research such as presented here is ideal for screening and 
preliminary investigations, but cannot speak much towards the efficacy of the same 
preparations in the organismal context. When animal models are employed, it would be 
beneficial to look at physiological aspects beyond immunity. For example, since Echinacea 
preparations are taken mainly for infections, a rodent model of infection may offer the 
opportunity for histological (such as tissue damage) or pathophysiological (such as lung viral 
titer) inspection. In humans, symptom surveys may be incorporated. 
(3) Effects by storage conditions 
Much further research needs to be done in this arena. The stability and 
phytochemical changes in stored extracts over time needs immediate attention. For example, 
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it is clear how drying times and temperature impact on phytochemical concentrations in situ, 
especially for roots, but only one study has explored how prepared extract phytochemical 
composition may change with storage time or temperature. While the data presented in this 
dissertation provide some preliminary guidelines as to how these factors affect extract 
performance, more direct and controlled comparisons across storage techniques are critical to 
understanding the stability of extracts with time. 
Only one of our experiments (Chapter 3) included a biochemical component. It might 
be interesting to replicate the time course experiments and look at how relative 
concentrations of the purported bioactive molecules change during the course. Similar 
experiments could be done for storage temperature differences. However, it is important to 
note that in Chapter 3 we were unable to discern any correlation between concentrations of 
bioactive molecules and immune properties. 
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APPENDIX A. ABSTRACTS FROM NON-DISSERTATION PROJECTS: 
OTHER ECHINACEA PROJECTS 
This dissertation has focused on papers where I have been the primary investigator. 
Besides these endeavors, I have also assisted other members of my laboratory as well as 
members of other laboratories in their own Echinacea investigations. These endeavors are 
given in alphabetical order as none have currently been submitted for peer review. 
Kohut ML, Cunnick JE, Martin AE, Zhai Z, Senchina DS, Murphy PA, Loiacono CM, 
Janke BH, Yoon KJ (in preparation). Echinacea does not reduce viral titer but 
enhances IL 10, minimizes inflammation, and decreases Thl cytokines. Journal of 
Infectious Diseases. 
Several species of Echinacea have been used to treat the common cold and influenza-
type illnesses, yet evidence from clinical trials in support of Echinacea has been limited. A 
mouse model of influenza infection was used to determine the extent to which Echinacea 
may alter viral titer, lung pathology, and influenza-specific immune response. E. purpurea 
extract or vehicle control treatment was administered by gavage before and after influenza 
virus challenge. At six and 10 days post-infection, viral titer, pathology and immune 
responses were evaluated. Echinacea treatment did not reduce lung viral titer, but tended to 
minimize pathology. Anti-influenza IgM and IgG were not altered in Echinacea treated 
mice. At day 6 post-infection, IL-10 production was enhanced by Echinacea. At day 10 
post-infection the Echinacea treatment decreased influenza-specific IL-2 and IFNy. 
These findings suggest that Echinacea treatment does not reduce viral titer and does not 
enhance anti-influenza antibody. However, an earlier activation of anti-inflammatory factors 
(IL-10), and a subsequent reduction of the inflammatory Thl cytokine, IFNy was found in 
Echinacea-treated mice. Thus, the potential benefits of Echinacea in respiratory infection 
may be due to a reduction in inflammation rather than via antiviral or immunostimulatory 
actions. 
Martin AE, Senchina DS, Buss JE, Kohut ML (in preparation). Effects of Echinacea 
spp. extracts on macrophage interferon activities. Journal of Immunotherapy. 
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Phytomedicinal preparations from Echinacea spp. are commonly consumed to 
enhance immunity to upper respiratory viral infections such as influenza or rhinovirus. 
Previous investigations suggest that species of this genus may act most strongly on 
components of innate immunity, specifically cells such as macrophages. Interferons are a 
class of cytokines synthesized by leukocytes such as macrophages that assist cells in resisting 
viral replication. We hypothesized that one mechanism whereby Echinacea spp. extracts may 
enhance immunity is through modulating interferon-associated pathways of macrophages. 
To explore this hypothesis, we used herpes simplex models of infection in murine peritoneal 
macrophages or murine macrophage tumor cell lines. Treated cells were incubated with 
extracts from three different species (E. angustifolia, E. purpurea, E. tennesseensis) using 
different extraction methods, whereas control macrophages received only supplemental 
media. Treated cells incubated with extracts prior to infection did not show significantly 
enhanced viability or secretion of interferons alpha or beta as compared to control cells. 
Compared to macrophages not incubated with extracts, treated macrophages did not 
demonstrate enhanced guanlyate binding protein (GBP) production but did demonstrate 
enhanced inducible nitric oxide synthase (iNOS) production, regardless of whether the cells 
were infected or not. Of all species and extraction methods tested, a 50% ethanol/50% water 
extract of E. angustifolia was most active. Together, these results suggest that any potential 
antiviral activities of Echinacea spp. extracts are likely not mediated through macrophage-
associated interferon pathways. Methods developed here may be beneficial for further 
studies of Echinacea spp. extracts or other phytomedicinal preparations. 
Zhai Z, Liu Y, Wu L, Senchina DS, Wurtele ES, Murphy PA, Kohut ML, Cunnick JE 
(in preparation). Enhancement of innate and adaptive immune functions by multiple 
Echinacea species. Immunopharmacology and Immunotoxicology. 
Echinacea preparations are commonly used as non-specific immunomodulatory 
agents. Alcohol extracts from three widely used Echinacea species, E. angustifolia, E. 
pallida and E. purpurea, were investigated for immunomodulating properties. Male BALB/c 
mice were gavaged once/day with one of the Echinacea extracts 130 mg/kg or vehicle (5% 
151 
ethanol) for 7 days. All mice were immunized with sheep red blood cells (sRBC) 4 days prior 
to sacrifice. The no-gavage control received only an injection of sRBC. Peripheral blood was 
collected for hematology and cell proliferation assays. Spleen cells were harvested for 
multiple immunological assays, including NK cell activity, cell subset distribution, 
lymphocyte proliferation, antibody response against sRBC (plaque forming cell assay), and 
cytokine production. Although the three Echinacea extracts had distinct profiles of metabol ic 
constituents as measured by HPLC, they induced similar changes in the percentage of 
immune cell populations and their biological functions, including the percentages of 
lymphocytes in spleen and peripheral blood and NK cell cytotoxicity. Antibody response to 
sRBC was significantly increased by Echinacea treatment even after covariance with 
changes in the percentage of CD 19+ cells (B cells). In the presence of Con A, splenocytes 
from E. angustifolia- or E. pallida-treated mice demonstrated significantly higher T cell 
proliferation. In addition, the Echinacea treatment significantly altered the cytokine 
production by mitogen-stimulated splenic cells. Three herbal extracts significantly increased 
IFN-y production, but inhibited the release of TNF-a and IL-1(3. Taken together, these 
findings demonstrated that Echinacea is a wide-spectrum immunomodulator that could 
modulate both innate and adaptive immune response. 
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APPENDIX B. ABSTRACTS FROM NON DISSERTATION PROJECTS: 
IMMUNOBIOLOGY 
While my dissertation proper focused on the medical botany of the genus Echinacea, 
I also assisted with several other investigations pertaining to immunobiology and health 
during my tenure as a PhD student in the interdepartmental immunobiology program. The 
majority of these projects focused on exercise immunology. At the behest of my major 
professor, I have included the citations and abstracts from these investigations below to better 
reflect my total research contributions while at Iowa State University. They are given in 
chronological order beginning with the most recent. 
Kohut ML, Senchina DS (submitted to Clinical Interventions in Ageing). 
"Immunological outcomes of exercise in older adults." 
Ageing is associated with numerous physiological changes. Immunosenescence is a 
term coined to represent changes to the immune system associated with ageing. While most 
studies have focused on age-related declines in immune function, it is more accurate to think 
of immunosenescence as a state of dysregulation because lymphocytes respond 
heterogeneously to ageing. In this review, we will explore the current knowledge regarding 
exercise and immunosenescence, how the implementation of an appropriate physical activity 
program in older populations may lead to beneficial clinical outcomes, and how 
inappropriate exercise may detrimentally impact health. 
Kohut ML, Martin AE, Senchina DS, Lee W (2005). "Glucocorticoids produced during 
exercise may be necessary for virus-induced IL-2 and cell proliferation, whereas both 
catecholamines and glucocorticoids may be required for adequate immune defense to 
viral infection." Brain, Behavior, and Immunity 19(5): 423-435. 
Prolonged, exhaustive exercise has been associated with impaired immune 
responsiveness and increased susceptibility to infection. We have shown that one bout of 
exercise to fatigue followed by viral challenge increases mortality. Stress hormones such as 
corticosteroids and catecholamines have been suggested as potential mediators of exhaustive 
exercise-induced immunosuppression. The purpose of this study was to determine whether 
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the administration of pharmacological agents to block the effect of catecholamines or 
corticosteroids would minimize the immunosuppression associated with this type of exercise. 
Mice either exercised to fatigue or were exposed to control conditions, and mice received an 
i.p. injection of either nadolol (beta-adrenergic receptor antagonist), RU486 (glucocorticoid 
type II receptor antagonist), or vehicle. Fifteen minutes post-exercise, mice were exposed to 
viral infection (Herpes simplex virus; HSV) via an intranasal route, and cells were collected 
3 days post-infection. The results showed that exercise suppressed HSV-specific cell 
proliferation, HSV-specific IL-2, and IFN-gamma, but did not alter these same immune 
parameters when the mitogen ConA was used to stimulate cells. In addition, exercise reduced 
NK cell cytotoxicity, alveolar cell TNFalpha, and peritoneal IL-lbeta, but did not affect IL-
10. The pharmacological blockade did not attenuate the exercise-associated 
immunosuppression. In fact, RU486 treatment exacerbated the exercise-induced decline in 
HSV-induced IL-2 production and cell proliferation. RU486 and nadolol treatment also 
tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-lbeta (RU486 only) 
in both exercise and control mice, suggesting that stress hormones may be necessary during 
infection for optimal responsiveness. These findings suggest that suppression of immune 
defenses during viral infection persists for at least 3 days post-exercise, and stress hormones 
may be essential for optimal immune defense to viral challenge, rather than detrimental. 
Kohut ML, Senchina DS (2004). "Reversing age-associated immunosenescence via 
exercise." Exercise Immunology Review 10: 6-41. 
Decreases in immune responsiveness with age are thought to contribute to the 
increased incidence and severity of infectious disease among the elderly. Several 
interventions, including exercise, have been proposed to restore immune function in older 
populations. The findings from some, but not all studies, support the possibility that exercise 
may attenuate immunosenescence. In recent years, the role of exercise in modulating immune 
response has been examined using models that may have clinical relevance, such as the 
response to vaccines and novel antigens. Taken together, the accumulated data suggest that 
exercise may be an efficacious therapy for restoring immune function in the elderly. In 
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general, long term exercise interventions appear to show the most promise. Exercise related 
improvements have been reported with respect to antibody titre, T cell function, macrophage 
response, alterations of the T(H)1/T(H)2 cytokine balance, the level of pro-inflammatory 
cytokines, and changes in naive/memory cell ratio. However, current data is minimal, and 
many questions remain including: the mechanisms that are involved, the potential clinical 
impact, the appropriate type or dose of exercise, and whether the benefits extend to all 
populations including frail, older adults. This review summarizes the major findings of these 
studies and proposes directions for future exploration. 
Kohut ML, Senchina DS, Madden KS, Martin AE, Felten DL, Moynihan JA (2004). 
"Age effects on macrophage function vary by tissue site, nature of stimulant, and 
exercise behavior." Experimental Gerontology 39(9): 1347-1360. 
We explored the effects of aging on macrophage function in male BALB/c mice from 
three age groups: young (2 months), middle-aged (12 months), and old (21 months). 
Macrophages were collected from alveoli, peritonea, and spleens of each age group. Cells 
were cultured in vitro with LPS or LPS+IFN-gamma and assayed for production of IL-1, IL-
12, NO, and TNF-alpha. Using herpes simplex virus-1, age-related changes in intrinsic 
antiviral resistance (plaque assay) and extrinsic antiviral resistance (NO and TNF-alpha 
production) were determined in alveolar and/or peritoneal macrophages. Effects of chronic 
exercise on age-related macrophage changes were examined. In vitro, macrophages from the 
alveoli and spleen of older mice generally produced more cytokine and NO compared to 
younger counterparts. Conversely, macrophages from the peritonea of older mice generally 
produced less cytokine and NO in vitro compared to younger counterparts. Alveolar 
macrophages from both old and young mice showed higher intrinsic antiviral resistance to 
HSV-1 compared to middle-aged mice, while peritoneal macrophages from young mice 
showed reduced intrinsic resistance compared to those from both middle-aged and old mice. 
When challenged with HSV-1, a trend towards decreased peritoneal macrophage production 
of TNF-alpha and decreased alveolar macrophage production of IL-12 with advancing age 
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was found. Chronic moderate exercise tended to reverse age-associated changes in 
macrophage function in old mice. 
Zeman CL, Depken DE, Senchina DS (2003). "Roma health issues: A review of the 
literature and discussion." Ethnicity and Health 8(3): 223-249. 
OBJECTIVES: Roma health issues are under-studied from a comprehensive, 
epidemiological perspective. The Roma peoples (including 'Travellers') have been living in 
and around Central and Eastern Europe for centuries, and may be one of the oldest 
systematically oppressed minority groups in Europe. This review examines the research 
literature in regard to the health and epidemiology of this group with the aim of examining 
the breadth and depth of the literature and reflecting on the primary and applied research 
needed to address the health needs of Roma groups. DESIGN: Internet, database and 
ancestral searches were conducted via such electronic databases as Medline and PubMed. 
Ancestral searches involved consulting previous literature reviews in select topical areas and 
obtaining all appropriate, primary literature. The time parameters of the search began with 
the year 1990 to current but was later expanded to 1985-2003 in order to capture slightly 
older published work. RESULTS: This paper describes what is known concerning Roma 
health via a review of the published studies, with special emphasis on population health and 
epidemiological studies. One hundred and twenty-nine articles are reviewed and discussed. 
The majority of research (50%) examines the genetic characteristics of this group. 
CONCLUSIONS: Surveillance and population health indices for this international minority 
population is scarce to lacking in the published literature. Concluding comments focus on the 
unique character of the study population and the need for scientific studies of Roma health 
issues and the cultural concerns which might affect them. 
156 
APPENDIX C. ABSTRACTS FROM NON-DISSERTATION PROJECTS: OTHER 
DISCIPLINES 
While my dissertation proper focused on the medical botany of the genus Echinacea, 
I also conducted several other investigations unrelated to immunobiology or health during 
my tenure as a PhD student. These investigations fall into three main categories: (1) my 
research conducted as a PhD student under Dr. Jonathan F. Wendel in the botany program 
from 2000-2002, before transferring to the immunobiology program; (2) my independent 
research on poison ivy, Toxicodendron radicans subsp. negundo, initiated in 2001; and (3) 
other independent side projects. They are given in chronological order beginning with the 
most recent. 
Senchina DS (accepted for publication). "Ethnobotany of poison ivy, poison oak, and 
relatives (Toxicodendron spp., Anacardiaceae): Veracity of historical accounts." 
Rhodora. 
Flistorical accounts detail numerous uses for poison ivy, poison oak, and other 
American Toxicodendron spp. (Anacardiaceae), despite their toxicity. The veracity of these 
accounts has recently been called into question by several sources. In this investigation, a 
multidisciplinary, hypothesis-driven approach was used to critically evaluate the veracity of 
such accounts by employing field studies, laboratory experiments, and literature review. 
Accounts regarding uses in textile production or religious rites were found to be more 
feasible to evaluate than those pertaining to cooking or medicine. Findings from this study 
suggest a new interpretation of such accounts and provide novel information regarding both 
the biology and ethnobotany of these plants. 
Senchina DS (2005). "Humans and poison ivy: a love/hate relationship." Herbarist 71: 
28-33. 
Poison ivy—its name alone evokes negative emotions, even from people who may 
never have been in contact with or seen the plant. We're taught from an early age poison 
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ivy's bedeviling attributes, namely, its seemingly stealthy ability to cause exceedingly itchy 
rashes in susceptible individuals. However, dermatitis is only half the story of humans' 
history with poison ivy. Numerous societies have discovered and utilized several beneficial 
aspects of poison ivy, including medicinal, domestic, religious, economic, and industrial 
purposes. In this article, I endeavor to elaborate on the positive qualities of poison ivy, and 
to demonstrate that humans and poison ivy have been engaged in a love/hate relationship for 
several centuries. 
Senchina DS (2005). "Beetle interactions with poison ivy and poison oak 
(Toxicodendron P. Mill. sect. Toxicodendron, Anacardiaceae)." Coleopterists Bulletin 
59(3): 328-334. 
Fifty years ago, The Coleopterists Bulletin featured a series of articles on beetles and 
their interactions with the plant genus Toxicodendron P. Mill, section Toxicodendron (the 
poison ivies and poison oaks). Subsequent to the series, little progress has been made towards 
a better understanding of these relationships. The present work uses both original 
observations from field studies as well as a historical review of previous data to synthesize a 
more robust picture of colcopteran-Toxicodendron relationships. In addition to enumerating 
previously unrecognized associations, this paper demonstrates that numerous coleopteran 
taxa interact with Toxicodendron spp. in both mutualistic and parasitic capacities. 
Senchina DS (2005). "A critical review of herbal remedies for poison ivy dermatitis." 
HerbalGram 66: 34-48. 
Poison ivy is well known for the painful, sometimes long-lasting lesions it may afflict 
on sensitive individuals. The plant, a member of the family Anacardiaceae, is known by 
several Latin binomials in the scientific and botanical literature: Toxicodendron radicans (L.) 
Kuntze, T. rydbergii (Small ex Rydb.) Greene, and Rhus radicans (L.). A bewildering 
number of herbal remedies, which vary widely in efficacy, are suggested by both the popular 
and scientific literature for treating poison ivy dermatitis (hereafter Toxicodendron 
dermatitis, TD). This critical review summarizes the existing medical data relating to the 
capability of these plants to heal inflammatory skin disorders such as TD. Due largely to a 
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lack of research, many remedies have scientifically unproven efficacy, such as gumweed 
('Grindelia spp. Willd., Asteraceae). Other recommended remedies have scientifically 
disproven efficacy. An especially poignant example is jewelweed (.Impatiens capensis 
Meerb. and I. pallida Nutt., Balsaminaceae), perhaps the most popular traditional herbal 
remedy for treating TD, which has been discredited by a number of studies. Though these 
findings may at first seem disheartening, there are several herbal remedies that have 
demonstrated efficacy in treating inflammatory skin conditions similar to TD. Among this 
category are echinacea, aka purple coneflower (.Echinacea spp. Moench, Asteraceae) and 
witch hazel (Hamamelis virginiana L., Hamamelidaceae). Continuing research in the field 
will likely expand this list in upcoming years. 
Senchina DS (2005). "A historical survey of botanical exploration in Antarctica." 
Huntia 12(1): 31-69. 
This article reviews the major botanical discoveries made in Antarctica during the last 
200 years as well as the individuals who made them. An overview of Antarctic plant life is 
presented first. The importance of Antarctic botany is then discussed, emphasizing the 
field's contribution to our current understanding of biodiversity, the evolution of plant life, 
plant physiology and reproduction, ecology, geology, and extraterrestrial studies. Current 
historical problems in Antarctic botany are identified, including its slow growth and 
development, the scattered nature of botanical data, and the lack of a unified taxonomy. 
Next, the botanical discoveries and the expeditions from which they occurred are discussed. 
For the time period spanning 1800-1945, these discoveries are organized chronologically. 
Discoveries since 1945 are organized thematically, paralleling a historic shift in emphasis 
from exploration to science. These events are accompanied by an analysis of the political 
and social climate that helped shape them. Finally, some concluding remarks are made on 
the history and development of Antarctic botany as a scientific entity. 
Senchina DS (2004). "Herbarium specimens of Toxicodendron P. Mill, section 
Toxicodendron (Anacardiaceae) as tools for teaching basic concepts in plant taxonomy." 
Vulpia 3(2): 51-79. 
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Four undergraduate lesson plans are presented utilizing herbarium specimens of 
Toxicodendron sect. Toxicodendron (the poison ivies, oaks, and sumacs) to teach basic 
concepts of plant taxonomy. The benefits of using this taxon in the post-secondary 
classroom are discussed. Tables within the text and sub-sections within the lesson plans are 
provided to assist instructors with integrating these lesson suggestions into their pre-existing 
curricula. 
Senchina DS (2003). "Poison ivy: painful to touch, painful to classify." Wild/lower 
19(3): 16-18. 
Poison ivy's reputation for causing blistery, itchy rashes is well known from an early 
age. Botanists have had trouble with poison ivy for an additional reason: it and related 
species are difficult to classify. What is it about poison ivy that causes everyone so many 
problems? The article takes a closer look at poison ivy by examining poison ivy's 
classification and identification, the chemicals in poison ivy and the allergic reactions they 
prompt our bodies to produce, ways to prevent and treat poison ivy reactions (including 
plants that have been used historically), and poison ivy's benefits for both the environment 
and humans. 
Senchina DS, Alvarez I, Cronn RC, Liu B, Rong J, Noyes RD, Paterson RH, Wing RA, 
Wilkens TA, Wendel JF (2003). "Rate variation among nuclear genes and the age of 
polyploidy in Gossypium." Molecular Biology and Evolution 20(4): 633-643. 
Molecular evolutionary rate variation in Gossypium (cotton) was characterized using 
sequence data for 48 nuclear genes from both genomes of allotetraploid cotton, models of its 
diploid progenitors, and an outgroup. Substitution rates varied widely among the 48 genes, 
with silent and replacement substitution levels varying from 0.018 to 0.162 and from 0.000 to 
0.073, respectively, in comparisons between orthologous Gossypium and outgroup 
sequences. However, about 90% of the genes had silent substitution rates spanning a more 
narrow threefold range. Because there was no evidence of rate heterogeneity among lineages 
for any gene and because rates were highly correlated in independent tests, evolutionary rate 
is inferred to be a property of each gene or its genetic milieu rather than the clade to which it 
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belongs. Evidence from approximately 200,000 nucleotides (40,000 per genome) suggests 
that polyploidy in Gossypium led to a modest enhancement in rates of nucleotide substitution. 
Phylogenetic analysis for each gene yielded the topology expected from organismal history, 
indicating an absence of gene conversion or recombination among homoeologs subsequent to 
allopolyploid formation. Using the mean synonymous substitution rate calculated across the 
48 genes, allopolyploid cotton is estimated to have formed circa 1.5 million years ago 
(MY A), after divergence of the diploid progenitors about 6.7 M Y A. 
Wendel JF, Cronn RC, Alvarez I, Liu B, Small RL, Senchina DS (2002). "Intron size 
and genome size in plants." Molecular Biology and Evolution 19(12): 2346-2352. 
No abstract available. 
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